stella
← For Researchers/Lp(a)/Research Sites

Lp(a) Research Sites

Sites currently running trials · ranked by activity

EndometriosisLong COVIDALSPTSDSickle Cell DiseaseLupusProstate CancerMenopauseLp(a)

2291 sites · 2789 trials · September 2026

Recruiting
Opening soon
Active · not recruiting
1

Jacksonville Center for Clinical Research

Jacksonville · Florida · United States

5 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
2

Virginia Heart

Falls Church · Virginia · United States

5 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
3

Intermountain Medical Center

Murray · Utah · United States

4 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
4

Advara HeartCare Joondalup

Joondalup · Australia

4 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
5

Eclipse Clinical Research

Tucson · Arizona · United States

4 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
6

National Heart Institute

Beverly Hills · California · United States

4 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
7

Vector Clinical Trials

Las Vegas · Nevada · United States

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
8

Eastside Research Associates

Redmond · Washington · United States

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
9

Nightingale Research

Adelaide · Australia

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
10

Advara HeartCare Leabrook

Leabrook · Australia

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
11

USC Clinical Trials Brisbane (South Bank)

South Brisbane · Australia

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
12

Clinitrials

West Perth · Australia

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
13

Semmelweis University

Budapest · Hungary

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
14

CHUAC-Complejo Hospitalario Universitario A Coruña

A Coruña · Spain

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
15

Parc de Salut Mar - Hospital del Mar

Barcelona · Spain

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
16

Hospital Universitario Reina Sofia

Córdoba · Spain

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
17

Hospital Universitario Ramón y Cajal

Madrid · Spain

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
18

Hospital Universitario Virgen Del Rocio

Seville · Spain

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
19

Hospital General Universitario de Valencia

Valencia · Spain

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
20

Bristol Royal Infirmary

Bristol · United Kingdom

3 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
21

Johns Hopkins University

Columbia · Maryland · United States

3 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
22

Anderson Medical Research

Ft. Washington · Maryland · United States

3 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
23

Birmingham Clinical Research

Birmingham · Alabama · United States

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
24

310 Clinical Research

Inglewood · California · United States

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
25

Excel Medical Clinical Trials

Boca Raton · Florida · United States

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
26

North Georgia Clinical Research

Woodstock · Georgia · United States

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
27

Ascension Saint Agnes Heart Care

Baltimore · Maryland · United States

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
28

Walker Family Care

Little River · South Carolina · United States

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
29

Victorian Heart Hospital

Clayton · Australia

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
30

Fusion Clinical Research

Norwood · Australia

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
31

Ecogene-21

Chicoutimi · Canada

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
32

North York Diagnostic and Cardiac Centre

North York · Canada

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
33

Victoria Heart Institute Foundation

Victoria · Canada

3 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
34

Research Site

Jacksonville · Florida · United States

2 trials
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
AZD4954 safety and activity tested in healthy volunteers and patients with high cholesterol or elevated lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
35

Research Site

Port Orange · Florida · United States

2 trials
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
AZD4954 safety and activity tested in healthy volunteers and patients with high cholesterol or elevated lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
36

Research Site

Brooklyn · New York · United States

2 trials
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
AZD4954 safety and activity tested in healthy volunteers and patients with high cholesterol or elevated lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
37

Research Site

San Antonio · Texas · United States

2 trials
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
AZD4954 safety and activity tested in healthy volunteers and patients with high cholesterol or elevated lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
38

UCSD - Altman Clinical and Translational Research Institute (ACTRI)

La Jolla · California · United States

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
39

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance · California · United States

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
40

Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care

Fort Lauderdale · Florida · United States

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
41

Inpatient Research Clinic

Miami Lakes · Florida · United States

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
42

CARE Institute - High Desert

Meridian · Idaho · United States

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
43

Heart and Vascular Research at WellSpan Health

York · Pennsylvania · United States

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
44

Carilion Clinic

Roanoke · Virginia · United States

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
45

Core Research Group

Brisbane · Australia

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
46

Advara HeartCare - Burwood

Burwood · Australia

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
47

AIM Research

Merewether · Australia

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
48

Advara HeartCare - Mulgrave

Mulgrave · Australia

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
49

Fakultni Nemocnice u sv. Anny v Brne

Brno · Czechia

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
50

EFERTUS healthcare s.r.o.

Brno · Czechia

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
51

Óbudai Egészségügyi Centrum

Budapest · Hungary

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
52

Ziekenhuis St. Jansdal

Harderwijk · Netherlands

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
53

VieCuri Medisch Centrum, locatie Venlo

Venlo · Netherlands

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
54

Hospital Insular de Gran Canaria

Las Palmas de Gran Canaria · Spain

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
55

Hospital Clinico San Carlos

Madrid · Spain

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
56

Hospital Universitario Virgen Macarena

Seville · Spain

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
57

FutureMeds - Birmingham

Birmingham · United Kingdom

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
58

Cheadle Community Hospital

Cheadle · United Kingdom

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
59

Lister Hospital

Stevenage · United Kingdom

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
60

FutureMeds Teesside - Middlefield Centre

Stockton-on-Tees · United Kingdom

2 trials
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
61

Heart Center Research Llc

Huntsville · Alabama · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
62

Mobile Heart Specialists

Mobile · Alabama · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
63

Mercy Gilbert Medical Center

Gilbert · Arizona · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
64

Valley Clinical Trials

Northridge · California · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
65

Manshadi Heart Institute

Stockton · California · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
66

Bridgeport Hospital

Bridgeport · Connecticut · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
67

Chase Medical Research LLC

Waterbury · Connecticut · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
68

Peace River Cardiovascular Center

Port Charlotte · Florida · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
69

Progressive Medical Research

Port Orange · Florida · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
70

Henry Ford Hospital

Detroit · Michigan · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
71

University Of Minnesota

Minneapolis · Minnesota · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
72

StudyMetrix Research

City of Saint Peters · Missouri · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
73

Lenox Hill Hospital

New York · New York · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
74

Northwell Health Physician Peconic

Riverhead · New York · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
75

Medication Management LLC

Greensboro · North Carolina · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
76

Ohio State University

Columbus · Ohio · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
77

Monument Health Clinical Research

Rapid City · South Dakota · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
78

Baylor College Of Medicine

Houston · Texas · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
79

Carient Heart and Vascular

Manassas · Virginia · United States

2 trials
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
80

Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC

Gilbert · Arizona · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
81

Clinical Research Institute of Arizona (CRI) - Sun City West

Sun City West · Arizona · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
82

Pima Heart

Tucson · Arizona · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
83

Neighborhood Healthcare Institute of Health

Escondido · California · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
84

Care Access - Huntington Beach

Huntington Beach · California · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
85

Scripps Whittier Diabetes Institute

La Jolla · California · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
86

UCLA South Bay Endocrinology

Torrance · California · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
87

University of Colorado Anschutz Medical Campus

Aurora · Colorado · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
88

Cardiology Associates of Fairfield County, P.C.

Stamford · Connecticut · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
89

Chase Medical Research, LLC

Waterbury · Connecticut · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
90

K2 Medical Research - Maitland

Maitland · Florida · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
91

Advanced Research for Health Improvement, LLC

Naples · Florida · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
92

Renstar Medical Research

Ocala · Florida · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
93

Florida Institute For Clinical Research, LLC

Orlando · Florida · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
94

Care Access - Tamarac

Tamarac · Florida · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
95

Care Access - Tampa

Tampa · Florida · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
96

Southeastern Clinical Research Institute

Augusta · Georgia · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
97

Center for Advanced Research & Education

Gainesville · Georgia · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
98

NSC Research

Johns Creek · Georgia · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
99

Great Lakes Clinical Trials - Ravenswood

Chicago · Illinois · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
100

Clinical Investigation Specialists

Gurnee · Illinois · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
101

Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative

Springfield · Illinois · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
102

Indiana University Health Methodist Hospital

Indianapolis · Indiana · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
103

Iowa Diabetes and Endocrinology Research Center

West Des Moines · Iowa · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
104

Cotton O'Neil Clinical Research Center

Topeka · Kansas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
105

Flourish Research - Bowie

Bowie · Maryland · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
106

Centennial Medical Group

Columbia · Maryland · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
107

Brigham and Women's Hospital Diabetes Program

Boston · Massachusetts · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
108

Care Access - Quincy

Quincy · Massachusetts · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
109

Revival Research Institute, LLC

Dearborn · Michigan · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
110

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

Troy · Michigan · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
111

Cardio Metabolic Institute

Somerset · New Jersey · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
112

IMA Clinical Research

Albuquerque · New Mexico · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
113

Care Access - Fayetteville

Fayetteville · North Carolina · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
114

Medication Management

Greensboro · North Carolina · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
115

Monroe Biomedical Research

Monroe · North Carolina · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
116

Accellacare - Raleigh

Raleigh · North Carolina · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
117

Centricity Research Columbus Ohio Multispecialty

Columbus · Ohio · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
118

Lehigh Valley Health Network

Allentown · Pennsylvania · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
119

Capital Area Research, LLC

Camp Hill · Pennsylvania · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
120

Abington Medical Specialists

Horsham · Pennsylvania · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
121

Penn Medicine: University of Pennsylvania Health System

Philadelphia · Pennsylvania · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
122

Clinical Research of Philadelphia

Philadelphia · Pennsylvania · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
123

Keystone Clinical Studies

Plymouth Meeting · Pennsylvania · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
124

Cardiology Consultants of Philadelphia Yardley

Yardley · Pennsylvania · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
125

Medical University of South Carolina

Charleston · South Carolina · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
126

PharmaTex Research

Amarillo · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
127

Velocity Clinical Research, Austin

Austin · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
128

UT Southwestern Medical Center

Dallas · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
129

Texas Health Research & Education Institute - Fort Worth

Fort Worth · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
130

Center for Cardiometabolic Disease Prevention/Baylor College of Medicine

Houston · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
131

Research Physicians Network, LLC

Houston · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
132

Biopharma Informatic, LLC

McAllen · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
133

Revival Research Institute, LLC

McKinney · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
134

Texas Institute of Cardiology, PA

McKinney · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
135

PRX Research

Mesquite · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
136

Sherman Clinical Research

Sherman · Texas · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
137

Rainier Clinical Research Center

Renton · Washington · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
138

Clinical Investigation Specialists

Kenosha · Wisconsin · United States

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
139

Buenos Aires Macula S.A

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
140

CIPREC

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
141

Instituto Médico Especializado (IME)

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
142

Consultorio Medico Dr Litvak Bruno

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
143

Consultorio Medico Investigador Principal Dr Besada

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
144

Glenny Corp. S.A.

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
145

Stat Research S.A.

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
146

Investigaciones Medicas Imoba Srl

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
147

Centro de Investigaciones Metabólicas (CINME)

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
148

CEMEDIC

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
149

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
150

Fundación Respirar

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
151

Centro Médico Arsema

Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
152

IDIM - Instituto de Investigaciones Metabólicas

Ciudad de Buenos Aires · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
153

Instituto de Cardiología "Juana F. Cabral"

Corrientes · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
154

Instituto de Investigaciones Clínicas Córdoba

Córdoba · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
155

Centro Médico Colón

Córdoba · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
156

CIPADI - Centro Integral de Prevencion y Atencion en Diabetes

Godoy Cruz · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
157

Centro de Investigaciones Clínicas Baigorria

Granadero Baigorria · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
158

CIMeL

Lanus · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
159

Centro de Investigaciones Médicas Mar del Plata

Mar del Plata · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
160

Instituto de Investigaciones Clínicas Mar del Plata

Mar del Plata · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
161

Instituto de Cardiología Wolff

Mendoza · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
162

Instituto De Investigaciones Clinicas Quilmes

Quilmes · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
163

DIM Clínica Privada

Ramos Mejía · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
164

Instituto Médico Río Cuarto

Río Cuarto · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
165

Fundacion Estudios Clinicos

Rosario · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
166

INECO Neurociencias Oroño

Rosario · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
167

Instituto Especialidades de la Salud Rosario

Rosario · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
168

Instituto Médico Catamarca IMEC

Rosario · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
169

Instituto de Investigaciones Clinicas Rosario

Rosario · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
170

Laboratorio de Hemostasia y Trombosis

Rosario · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
171

Hospital Provincial del Centenario

Rosario · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
172

Corporación Médica San Martín

San Martin · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
173

Centro Modelo de Cardiología

San Miguel de Tucumán · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
174

Investigaciones Clínicas Tucumán

San Miguel de Tucumán · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
175

Centro de Diagnóstico y Rehabilitación (CEDIR)

Santa Fe · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
176

Centro de Investigaciones Clinicas del Litoral

Santa Fe · Argentina

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
177

Box Hill Hospital

Box Hill · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
178

Royal Brisbane and Women's Hospital

Brisbane · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
179

Heart of Australia

Brisbane · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
180

Cholesterol Care

Brisbane · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
181

Barwon Health

Geelong · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
182

Clinitrials - Mandurah

Greenfields · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
183

University of the Sunshine Coast (UniSC) Clinical Trials - Meadowbrook

Meadowbrook · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
184

The AIM Centre / Hunter Diabetes Centre

Merewether · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
185

USC Clinical Trials Moreton Bay

Morayfield · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
186

USC Clinical Trials Sunshine Coast

Sippy Downs · Australia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
187

Krankenhaus St. Josef Braunau

Braunau am Inn · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
188

VIVIT

Feldkirch · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
189

Ordensklinikum Linz GmbH Elisabethinen

Linz · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
190

Konventhospital der Barmherzigen Brüder Linz

Linz · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
191

Landesklinikum Mistelbach

Mistelbach · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
192

Uniklinikum Salzburg

Salzburg · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
193

Universitätsklinikum St. Pölten

Sankt Pölten · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
194

Klinik Landstraße

Vienna · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
195

Zentrum für klinische Studien Dr Hanusch Gmbh

Vienna · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
196

Medizinische Universität Wien

Vienna · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
197

Universitaetsklinikum Allgemeines Krankenhaus Wien

Vienna · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
198

Klinik Hietzing

Vienna · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
199

Herz Zentrum Währing - Innere Medizin und Kardiologie | Alle Kassen und Privat

Vienna · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
200

Klinik Floridsdorf

Vienna · Austria

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
201

ZAS Middelheim

Antwerp · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
202

Imelda General Hospital

Bonheiden · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
203

Algemeen Ziekenhuis klina

Brasschaat · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
204

Centre Hospitalier Universitaire Brugmann

Brussels · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
205

Cliniques universitaires Saint-Luc

Brussels · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
206

Antwerp University Hospital

Edegem · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
207

Ziekenhuis Oost-Limburg, Campus St.-Jan

Genk · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
208

AZ Groeninge Campus Kennedylaan

Kortrijk · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
209

UZ Leuven

Leuven · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
210

AZ Sint-Maarten

Mechelen · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
211

AZ Oostende vzw

Ostend · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
212

AZ Delta vzw

Roeselare · Belgium

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
213

Centro de Pesquisa Clinica do Coracao

Aracaju · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
214

Hospital Universitário João de Barros Barreto

Belém · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
215

NUPEC - Cardio

Belo Horizonte · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
216

AngioKormann Blumenau

Blumenau · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
217

Chronos Pesquisa Clínica

Brasília · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
218

Instituto de Pesquisa clinica de Campinas

Campinas · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
219

Centro de Pesquisa Sao Lucas

Campinas · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
220

Quanta Diagnóstico e Terapia

Curitiba · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
221

Universidade Federal de Goias

Goiânia · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
222

Instituto Do Coracao De Marilia

Marília · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
223

Instituto Méderi de Pesquisa e Saúde

Passo Fundo · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
224

Hospital de Clinicas de Porto Alegre

Porto Alegre · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
225

Núcleo de Pesquisa Clínica do Rio Grande do Sul

Porto Alegre · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
226

Hospital Moinhos de Vento

Porto Alegre · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
227

Hospital Nossa Senhora da Conceição

Porto Alegre · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
228

IBPClin - Instituto Brasil de Pesquisa Clínica

Rio de Janeiro · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
229

Ruschel Medicina e Pesquisa Clínica

Rio de Janeiro · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
230

Praxis Pesquisa Medica

Santo André · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
231

Fundação Faculdade Regional de Medicina de São José do Rio Preto

São José do Rio Preto · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
232

Centro Internacional de Pesquisa Clínica (CIPES)

São José dos Campos · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
233

CPQuali Pesquisa Clínica

São Paulo · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
234

CPCLIN

São Paulo · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
235

Instituto Dante Pazzanese de Cardiology

São Paulo · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
236

CEPIC - Centro Paulista de Investigação Clínica

São Paulo · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
237

Incor - Instituto do Coracao

São Paulo · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
238

CEDOES

Vitória · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
239

Integral Pesquisa e Ensino

Votuporanga · Brazil

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
240

Diex Recherche Inc. Division Joliette

Joliette · Canada

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
241

Viacar Recherche Clinique

Longueuil · Canada

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
242

G A Research Associates

Moncton · Canada

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
243

Diex Recherche Inc. Division Trois-Rivieres

Trois-Rivières · Canada

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
244

Discovery Clinical Services

Victoria · Canada

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
245

Peking University First Hospital

Beijing · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
BSA204 injection safety assessed in Chinese adults with moderately elevated lipoprotein(a).
Bisirna Therapeutics (Suzhou) Co., Ltd.Ph 1NCT07551505 ↗
246

Peking University Third Hospital

Beijing · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
247

The First Hospital of Jilin University

Changchun · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
248

China-Japan Union Hospital

Changchun · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
249

Changde First People's Hospital

Changde · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
250

Sichuan Provincial People's Hospital

Chengdu · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
251

West China Hospital Sichuan University

Chengdu · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
252

2nd Affiliated Hospital Chongqing Medical Universi

Chongqing · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
253

Guangdong Provincial People's Hospital

Guangzhou · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
254

Zhejiang Provincial People's Hospital

Hangzhou · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
255

The First Hospital of Harbin Medical University

Harbin · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
256

The Second People's Hospital of Hefei

Hefei · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
257

Jinan Central Hospital

Jinan · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
258

Lishui Central Hospital

Lishui · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
259

The First Affiliated Hospital of Henan University of Science &Technology

Luoyang · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
260

Zhongshan Hospital,Fudan University

Shanghai · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
261

Siping Central People's Hospital

Siping · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
262

Chongqing Three Gorges Central Hospital

Wanzhou · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
263

Renmin Hospital of Wuhan University

Wuhan · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
264

Shaanxi provincial people's hospital

Xi'an · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
265

The Affiliated Hospital of Xuzhou Medical College

Xuzhou · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
266

Zigong First People's Hospital

Zigong · China

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
267

Kardiologická ambulance Brno

Brno · Czechia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
268

Angiocentrum Komorany

Prague · Czechia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
269

Poliklinika Lípa Centrum

Prague · Czechia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
270

Cardio Research, s.r.o

Zlín · Czechia

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
271

Sanos Clinic - Nordjylland

Gandrup · Denmark

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
272

Sanos Clinic

Herlev · Denmark

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
273

Sanos Clinic - Syddanmark

Vejle · Denmark

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
274

Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand

Dijon · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
275

Hopital Claude Huriez - CHU de Lille

Lille · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
276

Centre Hospitalier Saint Joseph - Saint Luc

Lyon · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
277

Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes

Nantes · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
278

Centre Hospitalier Universitaire de Nice - Hopital Pasteur

Nice · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
279

Pitie Salpetriere University Hospital

Paris · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
280

Hôpital Européen Georges Pompidou

Paris · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
281

Hôpital Bichat - Claude-Bernard

Paris · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
282

Hôpital Saint Antoine

Paris · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
283

CHU Strasbourg-Hautepierre

Strasbourg · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
284

CHU Rangueil

Toulouse · France

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
285

Universitätsklinikum Aachen

Aachen · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
286

Zentrum für klinische Studien Bad Homburg

Bad Homburg · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
287

Kardiologische Praxen im Spreebogen

Berlin · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
288

Charité Campus Virchow-Klinikum

Berlin · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
289

Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien

Dresden · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
290

Herzzentrum Dresden GmbH Universitätsklinik

Dresden · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
291

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
292

Cardioangiologisches Centrum Bethanien

Frankfurt · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
293

Cardiologicum Hamburg

Hamburg · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
294

Universitaetsklinikum Heidelberg

Heidelberg · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
295

Universitätsklinikum Leipzig

Leipzig · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
296

Herzzentrum Leipzig GmbH

Leipzig · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
297

Praxis Oedeme

Lüneburg · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
298

Otto-von-Guericke-Universität Magdeburg

Magdeburg · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
299

ze:ro ARZTPRAXEN

Mannheim · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
300

Deutsches Herzzentrum München

Munich · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
301

Institut für Diabetesforschung GmbH Münster

Münster · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
302

Universitätsklinikum Regensburg

Regensburg · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
303

Studienzentrum Herzklinik Ulm MVZ

Ulm · Germany

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
304

University General Hospital of Heraklion

Heraklion · Greece

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
305

University Hospital of Ioannina

Ioannina · Greece

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
306

AHEPA University General Hospital of Thessaloniki

Thessaloniki · Greece

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
307

Medifarma 98 Kft

Nyíregyháza · Hungary

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
308

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

Szeged · Hungary

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
309

Vita Verum Medical Egeszsegugyi Szolgaltato

Székesfehérvár · Hungary

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
310

KLES Dr. Prabhakar Kore Hospital & M.R.C

Belagavi · India

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
311

K care Hospital

Kanpur · India

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
312

Government Medical College - Kozhikode

Kozhikode · India

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
313

King George's Medical University

Lucknow · India

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
314

Vijan Hospital & Research Centre

Nashik · India

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
315

G.B. Pant Institute of Postgraduate Medical Education & Research

New Delhi · India

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
316

All India Institute of Medical Sciences

Raipur · India

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
317

Ospedale Cazzavillan di Arzignano

Arzignano · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
318

Ospedale di Baggiovara

Baggiovara · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
319

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

Bologna · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
320

Azienda Ospedaliero Universitaria S.Anna

Ferrara · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
321

Azienda Ospedaliera Universitaria Careggi

Florence · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
322

Ospedale San Martino

Genova · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
323

Centro Cardiologico Monzino

Milan · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
324

ASST Grande Ospedale Metropolitano Niguarda

Milan · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
325

Ospedale San Raffaele

Milan · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
326

Azienda Ospedale - Università Padova

Padova · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
327

Hospital Santa Maria della Misericordia in Perugia

Perugia · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
328

Fondazione G. Monasterio

Pisa · Italy

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
329

The Institute of Medical Science, Asahi Life Foundation

Chūōku · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
330

Hakodate Municipal Hospital

Hakodate · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
331

Tenyoukai Central Clinic

Kagoshima · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
332

Kanazawa University Hospital

Kanazawa · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
333

Miyazaki Medical Association Hospital

Miyazaki · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
334

Iwate Prefectural Central Hospital

Morioka · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
335

Nagoya City University Hospital

Nagoya · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
336

Osaka Keisatsu Hospital

Osaka · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
337

Osaka General Medical Center

Osaka · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
338

Sapporo Medical University Hospital

Sapporo · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
339

Japan Community Healthcare Organization Hokkaido Hospital

Sapporo · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
340

Tokuyama Central Hospital

Shūnan · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
341

National Cerebral and Cardiovascular Center

Suita · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
342

Kagawa Prefectural Central Hospital

Takamatsu · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
343

Osaka Medical and Pharmaceutical University Hospital

Takatsuki · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
344

Sekino Hospital

Toshimaku · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
345

Tsuchiura Kyodo General Hospital

Tsuchiura · Japan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
346

Fundación Cardiovascular de Aguascalientes A.C.

Aguascalientes · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
347

Instituto de Diabetes, Obesidad y Nutricion

Cuernavaca · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
348

Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.

Culiacán · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
349

Instituto Jalisciense de Investigacion en Diabetes y Obesidad

Guadalajara · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
350

Unidad de Investigación Clínica y Atención Médica HEPA S.C.

Guadalajara · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
351

Virgen Cardiovascular Research SC

Guadalajara · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
352

Instituto Cardiovascular de León S.C.

León · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
353

Grupo Medico Camino Sc

Mexico City · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
354

Hospital de Jésus, I.A.P.

Mexico City · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
355

Centro Médico Nacional Siglo XXI

Mexico City · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
356

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico City · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
357

Medical Care and Research SA de CV

Mérida · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
358

Accelerium Clinical Research

Monterrey · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
359

Cardiolink Clin Trials

Monterrey · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
360

UBAM Unidad Biomedica Avanzada Monterrey

Monterrey · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
361

Clínica García Flores SC

Monterrey · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
362

Centro de investigación y control metabólico

Monterrey · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
363

Centro de Atención e Investigación Cardiovascular del Potosí

San Luis Potosí City · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
364

Servicios Integrales Nova de Monterrey S.A. de C.V.

San Nicolás de los Garza · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
365

Medimanage Research

Tlalpan · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
366

Hospital Angeles Xalapa

Xalapa · Mexico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
367

Meander Medisch Centrum

Amersfoort · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
368

Amsterdam UMC, locatie AMC

Amsterdam · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
369

Ziekenhuis Gelderse Vallei

Ede · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
370

Tergooiziekenhuizen, locatie Hilversum

Hilversum · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
371

Leids Universitair Medisch Centrum

Leiden · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
372

Bravis Ziekenhuis, locatie Roosendaal

Roosendaal · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
373

Erasmus Medisch Centrum

Rotterdam · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
374

Universitair Medisch Centrum Utrecht

Utrecht · Netherlands

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
375

NZOZ Twoje Zdrowie EL Sp. z o. o.

Elblag · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
376

NZOZ Salvia CM

Katowice · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
377

Centrum Medyczne Linden

Krakow · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
378

Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET

Krakow · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
379

Poliklinika Kardiologiczna Serce

Leszno · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
380

Centra Medyczne Medyceusz

Lodz · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
381

Instytut Centrum Zdrowia Matki Polki

Lodz · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
382

Clinical Best Solutions

Lublin · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
383

Private Practice - Dr. Michał Tomaszewski

Lublin · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
384

Centrum Szybkiej Diagnostyki Kardiologicznej "Kardiomed" M. Żabówka E. Żabówka

Tarnów · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
385

4 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ

Wroclaw · Poland

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
386

Advanced Clinical Research, LLC

Bayamón · Puerto Rico

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
387

Nicodiab

Bucharest · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
388

Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului

Bucharest · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
389

Centrul Medical NutriLife

Bucharest · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
390

Spitalul Universitar de Urgență București

Bucharest · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
391

Mat Cord Biomedica S.R.L.

Buzău · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
392

Diamed Obesity

Galați · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
393

Clinica Korall

Satu Mare · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
394

Gensan S.R.L. - Policlinica Astra Sibiu

Sibiu · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
395

SC Dentosim Queen SRL - Centrul Medical Diamed

Târgu Mureş · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
396

Centrul Medical Mediab

Târgu Mureş · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
397

Mediab S.R.L.

Târgu Mureş · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
398

Private Practice - Dr. Cristian Podoleanu

Târgu Mureş · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
399

Cabinet Medical Dr.Geru

Timișoara · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
400

Institutul de Boli Cardiovasculare Timișoara

Timișoara · Romania

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
401

Daegu Catholic University Medical Center

Daegu · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
402

Gachon University Gil Medical Center

Namdong-gu · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
403

Seoul National University Bundang Hospital

Seongnam · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
404

Korea University Anam Hospital

Seoul · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
405

Kangbuk Samsung Hospital

Seoul · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
406

Severance Hospital, Yonsei University Health System

Seoul · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
407

Asan Medical Center

Seoul · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
408

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
409

Korea University Guro Hospital

Seoul · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
410

The Catholic University Of Korea St. Vincent's Hospital

Suwon · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
411

Ulsan University Hospital

Ulsan · South Korea

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
412

Hospital Clínic de Barcelona

Barcelona · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
413

Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval

Ferrol · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
414

Hospital Universitario Virgen Nieves

Granada · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
415

Hospital Infanta Elena

Huelva · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
416

Hospital Universitario de Jaen

Jaén · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
417

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
418

FutureMeds - Madrid

Madrid · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
419

Hospital Universitario 12 de Octubre

Madrid · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
420

Hospital Universitario Virgen de la Victoria

Málaga · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
421

Hospital Universitari Son Espases

Palma · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
422

Salut Sant Joan de Reus-Baix Camp (Edp)

Reus · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
423

Hospital Virgen del Camino

Sanlúcar de Barrameda · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
424

Hospital Universitario Marqués de Valdecilla

Santander · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
425

CHUS - Hospital Clinico Universitario

Santiago de Compostela · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
426

Hospital General de Segovia

Segovia · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
427

FutureMeds - Sevilla

Seville · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
428

Vithas Hospital Sevilla

Seville · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
429

Hospital Clinico de Valencia

Valencia · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
430

Hospital Virgen de las Montañas

Villamartín · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
431

Hospital Universitario Miguel Servet

Zaragoza · Spain

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
432

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
433

Chang Gung Memorial Hospital at Kaohsiung

Kaohsiung Niao Sung Dist · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
434

Chi Mei Medical Center

Tainan · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
435

National Taiwan University Hospital

Taipei · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
436

Cathay General Hospital

Taipei · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
437

Taipei Medical University Hospital

Taipei · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
438

Shin Kong Wu Ho-Su Memorial Hospital

Taipei · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
439

Taipei Veterans General Hospital

Taipei · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
440

Tri-Service General Hospital

Taipei · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
441

Chang Gung Medical Foundation-Linkou Branch

Taoyuan · Taiwan

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
442

Layton Medical Centre

Blackpool · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
443

Panthera Biopartners - North London

Enfield · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
444

Panthera Biopartners - Glasgow

Glasgow · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
445

Panthera Biopartners - Preston

Preston · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
446

Panthera Biopartners - Manchester

Rochdale · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
447

Panthera Biopartners - Sheffield

Sheffield · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
448

Sandwell General Hospital

West Bromwich · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
449

Panthera Clinic - York

York · United Kingdom

2 trials
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
450

Interventional Cardiology Medical Group

West Hills · California · United States

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
451

IMA Clinical Research

Monroe · Louisiana · United States

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
452

Icahn School of Medicine at Mount Sinai

New York · New York · United States

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
453

IMA Clinical Research Manhattan

New York · New York · United States

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
454

Zenos Clinical Research

Dallas · Texas · United States

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
455

IMA Clinical Research San Antonio

San Antonio · Texas · United States

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
456

Premier Clinical Trial Network

Hamilton · Canada

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3CompletedNCT07136012 ↗
457

The Third Xiangya Hospital of Central South University

Changsha · China

2 trials
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
BEBT-701 injection treats patients with mild-to-moderate high blood pressure and elevated cholesterol.
BeBetter Med IncPh 1 / Ph 2RecruitingNCT07368608 ↗
458

Department of Cardiology - Freiburg - Bad Krozingen

Freiburg im Breisgau · Germany

1 trial
Study tracking how heart disease risk biomarkers change over time in patients tested repeatedly.
University Hospital FreiburgNCT07817576 ↗
459

West China Hospital of Sichuan University

Chengdu · Sichuan · China

1 trial
Efficacy and safety study of oral HRS-5346 tablet for high-risk patients with elevated lipoprotein(a).
Shandong Suncadia Medicine Co., Ltd.Ph 2NCT07767513 ↗
460

Clinical Study Center

Dothan · Alabama · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
461

Clinical Study Center

Pomona · California · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
462

Clinical Study Center

Boca Raton · Florida · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
463

Clinical Study Center

Jacksonville · Florida · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
464

Clinical Study Center

Winter Park · Florida · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
465

Clinical Study Center

Indianapolis · Indiana · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
466

Clinical Study Center

High Point · North Carolina · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
467

Clinical Study Center

Philadelphia · Pennsylvania · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
468

Clinical Study Center

DeSoto · Texas · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
469

Clinical Study Center

Renton · Washington · United States

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
470

Clinical Study Center

Adelaide · Australia

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
471

Clinical Study Center

Melbourne · Australia

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
472

Clinical Study Center

Sydney · Australia

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
473

Clinical Study Center

Chicoutimi · Canada

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
474

Clinical Study Center

Hamilton · Canada

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
475

Clinical Study Center

Montreal · Canada

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
476

Clinical Study Center

Québec · Canada

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
477

Clinical Study Center

Toronto · Canada

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
478

Clinical Study Center

Vancouver · Canada

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
479

Clinical Study Center

Rehovot · Israel

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
480

Clinical Study Center

Christchurch · New Zealand

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
481

Clinical Study Center

Birmingham · United Kingdom

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
482

Clinical Study Center

Cambridge · United Kingdom

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
483

Clinical Study Center

Edinburgh · United Kingdom

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
484

Clinical Study Center

London · United Kingdom

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
485

Clinical Study Center

Manchester · United Kingdom

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
486

Clinical Study Center

Nottingham · United Kingdom

1 trial
VERVE-102 base-editing therapy disrupts a liver gene to lower cholesterol in patients with familial high cholesterol or early heart disease.
Verve Therapeutics, Inc.Ph 1RecruitingNCT06164730 ↗
487

Research Site

Aramil · Russia

1 trial
AZD0780 combined with rosuvastatin reduces blood cholesterol levels in adults with abnormal lipid profiles.
AstraZenecaPh 2NCT07218900 ↗
488

Research Site

Ivanovo · Russia

1 trial
AZD0780 combined with rosuvastatin reduces blood cholesterol levels in adults with abnormal lipid profiles.
AstraZenecaPh 2NCT07218900 ↗
489

Research Site

Moscow · Russia

1 trial
AZD0780 combined with rosuvastatin reduces blood cholesterol levels in adults with abnormal lipid profiles.
AstraZenecaPh 2NCT07218900 ↗
490

Research Site

Perm · Russia

1 trial
AZD0780 combined with rosuvastatin reduces blood cholesterol levels in adults with abnormal lipid profiles.
AstraZenecaPh 2NCT07218900 ↗
491

Research Site

Saint Petersburg · Russia

1 trial
AZD0780 combined with rosuvastatin reduces blood cholesterol levels in adults with abnormal lipid profiles.
AstraZenecaPh 2NCT07218900 ↗
492

UPenn

Philadelphia · Pennsylvania · United States

1 trial
Obicetrapib alone and combined with evolocumab tested to lower lipoprotein(a) in patients with elevated levels.
NewAmsterdam PharmaPh 2RecruitingNCT06496243 ↗
493

"Attikon" University General Hospital

Athens · Attica · Greece

1 trial
Study examines how lipoprotein(a) levels affect blood vessel stiffness, vessel function, and heart chamber performance in patients with elevated lipoprotein(a).
University of AthensRecruitingNCT07324902 ↗
494

Attikon University Hospital, 2nd Department of Cardiology, National and Kapodistrina University of Athens

Athens · Rimini 1 · Greece

1 trial
Study examines how lipoprotein(a) levels affect blood vessel stiffness, vessel function, and heart chamber performance in patients with elevated lipoprotein(a).
University of AthensRecruitingNCT07324902 ↗
495

Advanced Cardiovascular - Alexander City ( Site 0158)

Alexander City · Alabama · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
496

AMR Clinical Mobile ( Site 0149)

Mobile · Alabama · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
497

National Heart Institute ( Site 0113)

Beverly Hills · California · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
498

Headlands Research CTR Lincoln ( Site 0127)

Lincoln · California · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
499

Chase Medical Research, LLC ( Site 0163)

Waterbury · Connecticut · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
500

Soffer Health Institute ( Site 0123)

Hollywood · Florida · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
501

Westside Center for Clinical Research ( Site 0161)

Jacksonville · Florida · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
502

Inpatient Research Clinic ( Site 0110)

Miami Lakes · Florida · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
503

Clinical Research Trials of Florida ( Site 0101)

Tampa · Florida · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
504

Conquest Research LLC ( Site 0140)

Winter Park · Florida · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
505

Flourish Research - Bowie ( Site 0106)

Bowie · Maryland · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
506

Velocity Clinical Research Rockville ( Site 0146)

Rockville · Maryland · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
507

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0132)

Troy · Michigan · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
508

Minneapolis Heart Institute - Minneapolis ( Site 0130)

Minneapolis · Minnesota · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
509

Montana Medical Research, Inc. ( Site 0156)

Missoula · Montana · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
510

New Mexico Clinical Research & Osteoporosis Center ( Site 0119)

Albuquerque · New Mexico · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
511

Laurelton Heart Specialist PC ( Site 0155)

Rosedale · New York · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
512

Velocity Clinical Research, Durham ( Site 0145)

Durham · North Carolina · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
513

Remington-Davis, Inc. ( Site 0107)

Columbus · Ohio · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
514

Holston Medical Group ( Site 0117)

Kingsport · Tennessee · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
515

Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0154)

Houston · Texas · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
516

DM Clinical Research ( Site 0115)

Tomball · Texas · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
517

Carient Heart & Vascular - Manassas ( Site 0165)

Manassas · Virginia · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
518

Rainier Clinical Research Center ( Site 0116)

Renton · Washington · United States

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
519

North York Diagnostic and Cardiac Centre ( Site 0203)

North York · Ontario · Canada

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
520

Clinique des Maladies Lipidiques de Quebec ( Site 0201)

Québec · Quebec · Canada

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
521

Regionshospitalet Viborg ( Site 0507)

Viborg · Central Jutland · Denmark

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
522

Sanos Clinic - Nordjylland ( Site 0502)

Gandrup · North Denmark · Denmark

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
523

Klinikum Konstanz ( Site 0723)

Konstanz · Baden-Wurttemberg · Germany

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
524

Ambulantes Herzzentrum Kassel ( Site 0721)

Kassel · Hesse · Germany

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
525

Dedicated Research Site FutureMeds ( Site 0719)

Offenbach · Hesse · Germany

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
526

Studienzentrum Brinkum - Torsten Drescher & Dr. Lars Pohlmeier ( Site 0712)

Stuhr · Lower Saxony · Germany

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
527

zibp GmbH ( Site 0716)

Berlin · Germany

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
528

FutureMeds GmbH ( Site 0718)

Berlin · Germany

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
529

Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 0714)

Berlin · Germany

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
530

Medical Corporation Heishinkai OCROM Clinic ( Site 2403)

Suita · Osaka · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
531

Kumanomae Nishimura Naika Clinic ( Site 2407)

Arakawa City · Tokyo · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
532

Minamino Cardiovascular Hospital ( Site 2406)

Hachiōji · Tokyo · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
533

Kato Clinic of Internal Medicine ( Site 2402)

Katsushika-ku · Tokyo · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
534

Swing Nozaki Clinic ( Site 2405)

Musashino · Tokyo · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
535

Medical Corporation Heishinkai ToCROM Clinic ( Site 2404)

Shinjuku · Tokyo · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
536

Medical Corporation Hakuaikai Wellness Tenjin Clinic ( Site 2400)

Fukuoka · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
537

Midori Clinic ( Site 2401)

Nagasaki · Japan

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
538

Ziekenhuis Gelderse Vallei ( Site 1106)

Ede · Gelderland · Netherlands

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
539

Ziekenhuis St. Jansdal ( Site 1113)

Harderwijk · Gelderland · Netherlands

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
540

Bravis Ziekenhuis, locatie Roosendaal ( Site 1102)

Roosendaal · North Brabant · Netherlands

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
541

Antonius Ziekenhuis, locatie D&A Research and Genetics ( Site 1103)

Sneek · Provincie Friesland · Netherlands

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
542

Albert Schweitzer Ziekenhuis, locatie Dordwijk ( Site 1101)

Dordrecht · South Holland · Netherlands

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
543

Martini Ziekenhuis ( Site 1108)

Groningen · Netherlands

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
544

Vithas Hospital Sevilla ( Site 1401)

Castilleja de la Cuesta · Sevilla · Spain

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
545

Nuevas Tecnologías en D y E - Sevillaocío ( Site 1412)

Seville · Spain

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
546

HOCH Health Ostschweiz ( Site 1703)

Sankt Gallen · Canton of St. Gallen · Switzerland

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
547

Hopitaux Universitaires (Geneve) ( Site 1704)

Geneva · Switzerland

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
548

Luzerner Kantonsspital ( Site 1702)

Lucerne · Switzerland

1 trial
Trial testing MK-7262 combined with enlicitide to lower lipoprotein(a) and LDL cholesterol.
Merck Sharp & Dohme LLCPh 2RecruitingNCT07614984 ↗
549

Research Site

Dothan · Alabama · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
550

Research Site

Chandler · Arizona · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
551

Research Site

Phoenix · Arizona · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
552

Research Site

Huntington Beach · California · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
553

Research Site

Loma Linda · California · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
554

Research Site

Lomita · California · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
555

Research Site

Long Beach · California · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
556

Research Site

San Dimas · California · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
557

Research Site

Arvada · Colorado · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
558

Research Site

Colorado Springs · Colorado · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
559

Research Site

Waterbury · Connecticut · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
560

Research Site

Clearwater · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
561

Research Site

DeLand · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
562

Research Site

Hollywood · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
563

Research Site

Lakeland · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
564

Research Site

Miami Lakes · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
565

Research Site

Ocoee · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
566

Research Site

Plantation · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
567

Research Site

Tampa · Florida · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
568

Research Site

Atlanta · Georgia · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
569

Research Site

Conyers · Georgia · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
570

Research Site

Decatur · Georgia · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
571

Research Site

Hinesville · Georgia · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
572

Research Site

Peachtree Corners · Georgia · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
573

Research Site

Champaign · Illinois · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
574

Research Site

Chicago · Illinois · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
575

Research Site

Island Lake · Illinois · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
576

Research Site

Melrose Park · Illinois · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
577

Research Site

Palos Hills · Illinois · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
578

Research Site

Evansville · Indiana · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
579

Research Site

Waterloo · Iowa · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
580

Research Site

Derby · Kansas · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
581

Research Site

Lexington · Kentucky · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
582

Research Site

Louisville · Kentucky · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
583

Research Site

Zachary · Louisiana · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
584

Research Site

Annapolis · Maryland · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
585

Research Site

Beltsville · Maryland · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
586

Research Site

Bowie · Maryland · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
587

Research Site

Lutherville-Timonium · Maryland · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
588

Research Site

Oxon Hill · Maryland · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
589

Research Site

Flint · Michigan · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
590

Research Site

Troy · Michigan · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
591

Research Site

Kansas City · Missouri · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
592

Research Site

St Louis · Missouri · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
593

Research Site

Millville · New Jersey · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
594

Research Site

Astoria · New York · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
595

Research Site

The Bronx · New York · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
596

Research Site

Durham · North Carolina · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
597

Research Site

Morehead City · North Carolina · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
598

Research Site

Statesville · North Carolina · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
599

Research Site

Wilmington · North Carolina · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
600

Research Site

Winston-Salem · North Carolina · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
601

Research Site

Columbus · Ohio · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
602

Research Site

Dayton · Ohio · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
603

Research Site

Tulsa · Oklahoma · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
604

Research Site

Portland · Oregon · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
605

Research Site

Newport · Pennsylvania · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
606

Research Site

Smithfield · Pennsylvania · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
607

Research Site

Anderson · South Carolina · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
608

Research Site

Knoxville · Tennessee · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
609

Research Site

Houston · Texas · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
610

Research Site

Tomball · Texas · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
611

Research Site

Victoria · Texas · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
612

Research Site

Layton · Utah · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
613

Research Site

Salt Lake City · Utah · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
614

Research Site

South Jordan · Utah · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
615

Research Site

Richmond · Virginia · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
616

Research Site

Redmond · Washington · United States

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
617

Research Site

Burgas · Bulgaria

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
618

Research Site

Plovdiv · Bulgaria

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
619

Research Site

Razgrad · Bulgaria

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
620

Research Site

Sevlievo · Bulgaria

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
621

Research Site

Sofia · Bulgaria

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
622

Research Site

Varna · Bulgaria

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
623

Research Site

Veliko Tarnovo · Bulgaria

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
624

Research Site

Hamilton · Ontario · Canada

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
625

Research Site

Scarborough Village · Ontario · Canada

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
626

Research Site

Stouffville · Ontario · Canada

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
627

Research Site

Chicoutimi · Quebec · Canada

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
628

Research Site

Sherbrooke · Quebec · Canada

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3RecruitingNCT07619131 ↗
629

Research Site

Victoriaville · Quebec · Canada

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
630

Research Site

Aarhus · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
631

Research Site

Copenhagen · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
632

Research Site

Gandrup · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
633

Research Site

Herlev · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
634

Research Site

Herning · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
635

Research Site

Svendborg · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
636

Research Site

Vejle · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
637

Research Site

Viborg · Denmark

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
638

Research Site

Ahrensburg · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
639

Research Site

Berlin · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
640

Research Site

Bochum · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
641

Research Site

Gladbeck · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
642

Research Site

Hamburg · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
643

Research Site

Hanover · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
644

Research Site

Karlsruhe · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
645

Research Site

Leipzig · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
646

Research Site

Löhne · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
647

Research Site

Magdeburg · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
648

Research Site

Obertshausen · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
649

Research Site

Wiesbaden · Germany

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
650

Research Site

Budapest · Hungary

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
651

Research Site

Kaposvár · Hungary

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
652

Research Site

Zalaegerszeg · Hungary

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
653

Research Site

Haifa · Israel

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
654

Research Site

Jerusalem · Israel

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
655

Research Site

Kfar Saba · Israel

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
656

Research Site

Petah Tikva · Israel

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
657

Research Site

Częstochowa · Poland

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
658

Research Site

Gdynia · Poland

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3SUSPENDEDNCT07619131 ↗
659

Research Site

Katowice · Poland

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
660

Research Site

Lodz · Poland

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
661

Research Site

Lublin · Poland

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
662

Research Site

Warsaw · Poland

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
663

Research Site

Barcelona · Spain

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
664

Research Site

Figueres · Spain

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
665

Research Site

La Roca del Vallès · Spain

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
666

Research Site

Mataró · Spain

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
667

Research Site

Viladecans · Spain

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
668

Research Site

Ivano-Frankivsk · Ukraine

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
669

Research Site

Kyiv · Ukraine

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
670

Research Site

Lviv · Ukraine

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
671

Research Site

Uzhhorod · Ukraine

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
672

Research Site

Coventry · United Kingdom

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
673

Research Site

Knutsford · United Kingdom

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
674

Research Site

London · United Kingdom

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
675

Research Site

Orpington · United Kingdom

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
676

Research Site

Poole · United Kingdom

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
677

Research Site

Shipley · United Kingdom

1 trial
Efficacy study of laroprovstat/rosuvastatin combination drug for lowering LDL cholesterol in untreated patients.
AstraZenecaPh 3Opening soonNCT07619131 ↗
678

University of Alberta Hospital / Mazankowski Alberta Heart Institute

Edmonton · Alberta · Canada

1 trial
EHR-guided intervention to help more patients reach safe LDL cholesterol levels and prevent heart attacks.
University of AlbertaRecruitingNCT07685639 ↗
679

Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, 2900

Hellerup · Region Sjælland · Denmark

1 trial
Trial testing electronic letters to improve medication use and monitoring in heart disease patients with high cholesterol.
Tor Biering-SørensenNCT07382414 ↗
680

Valley Clinical Trials, Inc.

Northridge · California · United States

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
681

Merritt Island Medical Research, LLC

Merritt Island · Florida · United States

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
682

Clinical Site Partners, LLC dba Flourish Research

Winter Park · Florida · United States

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
683

Massachusetts General Hospital

Boston · Massachusetts · United States

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
684

Profound Research LLC

Farmington Hills · Michigan · United States

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
685

University of the Sunshine Coast (UniSC) Clinical Trials - Birtinya

Birtinya · Australia

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
686

Top Moravia Health

Brno · Czechia

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
687

Szabolcs Szatmár Bereg Vármegyei Oktatókórház

Nyíregyháza · Hungary

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
688

Medisch Spectrum Twente

Enschede · Netherlands

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
689

Alrijne Ziekenhuis, locatie Leiderdorp

Leiderdorp · Netherlands

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
690

Hospital Quiron Barcelona

Barcelona · Spain

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
691

Royal Lancaster Infirmary

Lancaster · United Kingdom

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
692

Lincoln County Hospital

Lincoln · United Kingdom

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
693

Futuremeds-Newcastle

Newcastle · United Kingdom

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07613294 ↗
694

The John Radcliffe Hospital

Oxford · United Kingdom

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
695

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield · United Kingdom

1 trial
Study of lepodisiran injection on coronary plaque in high-risk patients with elevated lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07613294 ↗
696

SEC Clinical Research LLC

Andalusia · Alabama · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
697

Clinical Research Inst of Arizona

Sun City West · Arizona · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
698

Cardiology and Medicine Clinic PA

Little Rock · Arkansas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
699

Cardiovascular Res Found

Beverly Hills · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
700

Valley Clinical Trials Inc

Covina · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
701

Diabetes Lipid Management Center

Huntington Beach · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
702

University of Calif Irvine Med Cntr

Irvine · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
703

Memorial Care Health System

Long Beach · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
704

Keck Medical Center USC

Los Angeles · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
705

Stanford University Medical Center

Palo Alto · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
706

University of California San Diego

San Diego · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
707

UCSF

San Francisco · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
708

Helping Hands Medical Associates INC

Santa Ana · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗
709

Interv Cardiology Med Grp

West Hills · California · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
710

Univ Of Color Anschutz Med Center

Aurora · Colorado · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
711

Hartford Hospital

Hartford · Connecticut · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
712

Excel Medical Clinical Trials LLC

Boca Raton · Florida · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
713

Bay Area Cardiology Assoc

Brandon · Florida · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
714

Advanced Research for Health Improvement LLC

Naples · Florida · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
715

East Coast Inst for Research LLC

Saint Augustine · Florida · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
716

Cardiology Partners Clinical Research Institute

Wellington · Florida · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
717

Piedmont Heart Institute

Atlanta · Georgia · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
718

Emory University

Atlanta · Georgia · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
719

Cardiovascular Consultants of S GA

Thomasville · Georgia · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
720

Rush University Medical Center

Chicago · Illinois · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
721

Advocate Lutheran General Childrens Hospital

Park Ridge · Illinois · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
722

Krannert Institute of Cardiology

Indianapolis · Indiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
723

Uni Of Iowa Hospitals And Clinics

Iowa City · Iowa · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
724

University of Kansas Hospital

Kansas City · Kansas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
725

Cotton O Neil Clinical Res Center

Topeka · Kansas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
726

Cardiovascular Associates Research

Covington · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
727

Louisiana Heart Center Research

Covington · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
728

CV Institute of the South

Houma · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
729

Horizon Research Grp

Lafayette · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗
730

Omega Clinical Research

Metairie · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
731

Tulane Center for Clinical Research

New Orleans · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
732

CV Ins of the South

Opelousas · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
733

Grace Research Llc

Shreveport · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
734

Louisiana Heart Center Research

Slidell · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
735

Southern Clinical Research

Zachary · Louisiana · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
736

Maine Health Cardiology

Scarborough · Maine · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
737

University of Maryland

Baltimore · Maryland · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
738

Sinai Ct for Throm Res and Drug Dev

Baltimore · Maryland · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
739

Johns Hopkins Univ School of Med

Baltimore · Maryland · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
740

Adventist HealthCare Shady Grove Medical Center

Rockville · Maryland · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
741

MGH

Boston · Massachusetts · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
742

Brigham and Womens Hosp Harvard Med School

Boston · Massachusetts · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
743

Wayne State University

Detroit · Michigan · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
744

AA Medical Research Center

Flint · Michigan · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
745

Western Michigan University

Kalamazoo · Michigan · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
746

McLaren Ctr Research Innovation

Petoskey · Michigan · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
747

Central Michigan University

Saginaw · Michigan · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
748

Metro Health Univ of MI Health

Wyoming · Michigan · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
749

Saint Johns Hospital

Maplewood · Minnesota · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
750

Minneapolis Heart Institute

Minneapolis · Minnesota · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
751

Belzoni Clinical Research

Belzoni · Mississippi · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
752

Stern Cardiovascular Foundation Inc

Southaven · Mississippi · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
753

Washington Univ School Of Medicine

St Louis · Missouri · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
754

Mercy Hospital St Louis

St Louis · Missouri · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
755

Quality Clinical Research

Omaha · Nebraska · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
756

Dartmouth Hitchcock Medical Center

Lebanon · New Hampshire · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
757

The Valley Hospital

Ridgewood · New Jersey · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
758

Overlook Medical Center

Summit · New Jersey · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
759

Northwell Health

Manhasset · New York · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
760

Weill Cornell Medical Center

New York · New York · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
761

Icahn School of Med at Mt Sinai

New York · New York · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
762

Novant Health Heart Vas Inst

Charlotte · North Carolina · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
763

Accellacare US Inc

Raleigh · North Carolina · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
764

Wake Forest University Baptist Medical Center

Winston-Salem · North Carolina · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
765

Akron Hospital Summa Health System

Akron · Ohio · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
766

Aultman Hospital

Canton · Ohio · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
767

Lindner Ctr At The Christ Hosp

Cincinnati · Ohio · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
768

Cleveland Clinic Foundation

Cleveland · Ohio · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
769

Rama Research LLC

Marion · Ohio · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
770

Lancaster General Health

Lancaster · Pennsylvania · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
771

Perelman School of Medicine

Philadelphia · Pennsylvania · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
772

Allegheny General Hospital

Pittsburgh · Pennsylvania · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
773

Cardiology Consultants of Philadelphia

Yardley · Pennsylvania · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
774

The Stern Cardiovascular Foundation

Germantown · Tennessee · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
775

Apex Cardiology Research Associates of Jackson

Jackson · Tennessee · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
776

Vanderbilt Univ Medi Cen

Nashville · Tennessee · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
777

Cardiovascular Res of Knoxville LLC

Powell · Tennessee · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
778

Soltero Cardiovascular Research Center

Dallas · Texas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
779

North Texas Endocrine Center

Dallas · Texas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
780

SW Family Medicine Associates

Dallas · Texas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
781

Grace Research

Marshall · Texas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
782

Northwest Houston Clinical Research PLLC

Tomball · Texas · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
783

Progressive Clinical Research

Bountiful · Utah · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
784

The University of Utah

Salt Lake City · Utah · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
785

Inova Fairfax Hospital

Falls Church · Virginia · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
786

Dominion Medical Associates

Richmond · Virginia · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
787

Harborview Medical Center

Seattle · Washington · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
788

Swedish Medical Center-Cardiovascular Research

Seattle · Washington · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
789

Univ of Washington Medical Center

Seattle · Washington · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
790

West Virginia University Hospital

Morgantown · West Virginia · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
791

St Luke s Medical Center Aurora

Milwaukee · Wisconsin · United States

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
792

Novartis Investigative Site

CABA · Buenos Aires F.D. · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
793

Novartis Investigative Site

Mar del Plata · Buenos Aires · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
794

Novartis Investigative Site

Ramos Mejía · Buenos Aires · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
795

Novartis Investigative Site

Córdoba · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
796

Novartis Investigative Site

San Miguel de Tucumán · San Miguel de Tucuman · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
797

Novartis Investigative Site

Rosario · Santa Fe Province · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
798

Novartis Investigative Site

Santa Fe · Santa Fe Province · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
799

Novartis Investigative Site

Buenos Aires · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
800

Novartis Investigative Site

Capital Federal · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
801

Novartis Investigative Site

Corrientes · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
802

Novartis Investigative Site

San Luis · Argentina

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
803

Novartis Investigative Site

Camperdown · New South Wales · Australia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
804

Novartis Investigative Site

Liverpool · New South Wales · Australia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
805

Novartis Investigative Site

Chemside · Queensland · Australia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
806

Novartis Investigative Site

Woolloongabba · Queensland · Australia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
807

Novartis Investigative Site

Clayton · Victoria · Australia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
808

Novartis Investigative Site

Perth · Western Australia · Australia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
809

Novartis Investigative Site

Graz · Austria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
810

Novartis Investigative Site

Innsbruck · Austria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
811

Novartis Investigative Site

Linz · Austria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
812

Novartis Investigative Site

Salzburg · Austria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
813

Novartis Investigative Site

Vienna · Austria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
814

Novartis Investigative Site

Brussels · Brussels Capital · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
815

Novartis Investigative Site

Genk · Limburg · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
816

Novartis Investigative Site

Aalst · Oost Vlaanderen · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
817

Novartis Investigative Site

Kortrijk · West-Vlaanderen · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
818

Novartis Investigative Site

Bruges · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
819

Novartis Investigative Site

Dendermonde · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
820

Novartis Investigative Site

Huy · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
821

Novartis Investigative Site

Mechelen · Belgium

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
822

Novartis Investigative Site

Vitória · Espírito Santo · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
823

Novartis Investigative Site

Salvador · Estado de Bahia · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
824

Novartis Investigative Site

Brasília · Federal District · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
825

Novartis Investigative Site

Goiânia · Goiás · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
826

Novartis Investigative Site

Belo Horizonte · Minas Gerais · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
827

Novartis Investigative Site

Juiz de Fora · Minas Gerais · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗
828

Novartis Investigative Site

Uberlândia · Minas Gerais · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
829

Novartis Investigative Site

Curitiba · Paraná · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
830

Novartis Investigative Site

Canoas · Rio Grande do Sul · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
831

Novartis Investigative Site

Porto Alegre · Rio Grande do Sul · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
832

Novartis Investigative Site

Blumenau · Santa Catarina · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
833

Novartis Investigative Site

Aracaju · Sergipe · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
834

Novartis Investigative Site

Campinas · São Paulo · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
835

Novartis Investigative Site

Ribeirão Preto · São Paulo · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
836

Novartis Investigative Site

Santo André · São Paulo · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
837

Novartis Investigative Site

Sao Jose Rio Preto · São Paulo · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
838

Novartis Investigative Site

São Paulo · São Paulo · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
839

Novartis Investigative Site

Rio de Janeiro · Brazil

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
840

Novartis Investigative Site

Burgas · Bulgaria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
841

Novartis Investigative Site

Pernik · Bulgaria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
842

Novartis Investigative Site

Pleven · Bulgaria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
843

Novartis Investigative Site

Plovdiv · Bulgaria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
844

Novartis Investigative Site

Rousse · Bulgaria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
845

Novartis Investigative Site

Sofia · Bulgaria

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
846

Novartis Investigative Site

Vancouver · British Columbia · Canada

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
847

Novartis Investigative Site

Victoria · British Columbia · Canada

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
848

Novartis Investigative Site

Oakville · Ontario · Canada

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
849

Novartis Investigative Site

Toronto · Ontario · Canada

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
850

Novartis Investigative Site

Lévis · Quebec · Canada

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
851

Novartis Investigative Site

Montreal · Quebec · Canada

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
852

Novartis Investigative Site

Québec · Quebec · Canada

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
853

Novartis Investigative Site

Beijing · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
854

Novartis Investigative Site

Lanzhou · Gansu · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
855

Novartis Investigative Site

Foshan · Guangdong · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
856

Novartis Investigative Site

Guangzhou · Guangdong · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
857

Novartis Investigative Site

Harbin · Heilongjiang · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
858

Novartis Investigative Site

Changsha · Hunan · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
859

Novartis Investigative Site

Baotou · Inner Mongolia · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
860

Novartis Investigative Site

Nanjing · Jiangsu · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
861

Novartis Investigative Site

Suzhou · Jiangsu · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
862

Novartis Investigative Site

Xuzhou · Jiangsu · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
863

Novartis Investigative Site

Changchun · Jilin · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
864

Novartis Investigative Site

Dalian · Liaoning · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
865

Novartis Investigative Site

Shenyang · Liaoning · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
866

Novartis Investigative Site

Jinan · Shandong · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
867

Novartis Investigative Site

Xian · Shanxi · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
868

Novartis Investigative Site

Chengdu · Sichuan · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
869

Novartis Investigative Site

Ürümqi · Xinjiang · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
870

Novartis Investigative Site

Hangzhou · Zhejiang · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
871

Novartis Investigative Site

Wenzhou · Zhejiang · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
872

Novartis Investigative Site

Shanghai · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
873

Novartis Investigative Site

Tianjin · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
874

Novartis Investigative Site

Xiamen · China

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
875

Novartis Investigative Site

Medellín · Colombia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
876

Novartis Investigative Site

Barranquilla · Colombia · Colombia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
877

Novartis Investigative Site

Bucaramanga · Santander Department · Colombia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
878

Novartis Investigative Site

Cali · Valle del Cauca Department · Colombia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
879

Novartis Investigative Site

Bogotá · Colombia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
880

Novartis Investigative Site

San Gil · Colombia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
881

Novartis Investigative Site

Kroměříž · Czech Republic · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
882

Novartis Investigative Site

Louny · Czech Republic · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
883

Novartis Investigative Site

Ostrava · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
884

Novartis Investigative Site

Ústí nad Labem · Czech Republic · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
885

Novartis Investigative Site

Brandýs nad Labem · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
886

Novartis Investigative Site

Brno · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
887

Novartis Investigative Site

Broumov · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
888

Novartis Investigative Site

Chlumec nad Cidlinou · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
889

Novartis Investigative Site

CZE · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
890

Novartis Investigative Site

Český Krumlov · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
891

Novartis Investigative Site

Hlučín · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
892

Novartis Investigative Site

Hodonín · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
893

Novartis Investigative Site

Jihlava · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
894

Novartis Investigative Site

Kolín · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
895

Novartis Investigative Site

Liberec · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
896

Novartis Investigative Site

Mariánské Lázně · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
897

Novartis Investigative Site

Mělník · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
898

Novartis Investigative Site

Most · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
899

Novartis Investigative Site

Olomouc · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
900

Novartis Investigative Site

Pardubice · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
901

Novartis Investigative Site

Polička · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
902

Novartis Investigative Site

Prague · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
903

Novartis Investigative Site

Přerov · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗
904

Novartis Investigative Site

Slaný · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
905

Novartis Investigative Site

Trutnov · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
906

Novartis Investigative Site

Třebíč · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
907

Novartis Investigative Site

Uherské Hradiště · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
908

Novartis Investigative Site

Valašské Meziříčí · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
909

Novartis Investigative Site

Zlín · Czechia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
910

Novartis Investigative Site

Aarhus N · Denmark

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
911

Novartis Investigative Site

Copenhagen · Denmark

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
912

Novartis Investigative Site

Esbjerg · Denmark

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
913

Novartis Investigative Site

Gistrup · Denmark

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
914

Novartis Investigative Site

Herlev · Denmark

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
915

Novartis Investigative Site

Roskilde · Denmark

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
916

Novartis Investigative Site

Viborg · Denmark

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
917

Novartis Investigative Site

Bron · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
918

Novartis Investigative Site

Chambray-lès-Tours · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
919

Novartis Investigative Site

Compiègne · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
920

Novartis Investigative Site

Grenoble · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
921

Novartis Investigative Site

Le Coudray · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
922

Novartis Investigative Site

Nantes · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
923

Novartis Investigative Site

Paris · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
924

Novartis Investigative Site

Toulouse · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
925

Novartis Investigative Site

Valenciennes · France

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
926

Novartis Investigative Site

Mannheim · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
927

Novartis Investigative Site

Muehldorf Am Inn · Bavaria · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
928

Novartis Investigative Site

Munich · Bavaria · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
929

Novartis Investigative Site

Weiden in Der Oberpfalz · Bavaria · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
930

Novartis Investigative Site

Frankfurt am Main · Hesse · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
931

Novartis Investigative Site

Hanover · Lower Saxony · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
932

Novartis Investigative Site

Cologne · North Rhine-Westphalia · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
933

Novartis Investigative Site

Essen · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
934

Novartis Investigative Site

Löhne · North Rhine-Westphalia · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
935

Novartis Investigative Site

Saint Ingbert · Saarland · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
936

Novartis Investigative Site

Chemnitz · Saxony · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
937

Novartis Investigative Site

Dresden · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
938

Novartis Investigative Site

Leipzig · Saxony · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
939

Novartis Investigative Site

Wittenberg · Saxony-Anhalt · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
940

Novartis Investigative Site

Jena · Thuringia · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
941

Novartis Investigative Site

Aachen · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
942

Novartis Investigative Site

Bad Homburg · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
943

Novartis Investigative Site

Bad Krozingen · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
944

Novartis Investigative Site

Bad Oeynhausen · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
945

Novartis Investigative Site

Bamberg · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
946

Novartis Investigative Site

Berlin · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
947

Novartis Investigative Site

Bielefeld · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
948

Novartis Investigative Site

Dessau · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
949

Novartis Investigative Site

Dortmund · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
950

Novartis Investigative Site

Gelnhausen · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
951

Novartis Investigative Site

Hamburg · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
952

Novartis Investigative Site

Kassel · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
953

Novartis Investigative Site

Lüneburg · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
954

Novartis Investigative Site

Magdeburg · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
955

Novartis Investigative Site

Meissen · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
956

Novartis Investigative Site

München · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
957

Novartis Investigative Site

Münster · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
958

Novartis Investigative Site

Potsdam · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
959

Novartis Investigative Site

Rüdersdorf · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
960

Novartis Investigative Site

Ulm · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
961

Novartis Investigative Site

Warendorf · Germany

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
962

Novartis Investigative Site

Athens · Greece

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
963

Novartis Investigative Site

Ioannina · Greece

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
964

Novartis Investigative Site

Larissa · Greece

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
965

Novartis Investigative Site

Thessaloniki · Greece

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
966

Novartis Investigative Site

Hong Kong · Hong Kong

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
967

Novartis Investigative Site

Debrecen · Hajdu Bihar Megye · Hungary

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
968

Novartis Investigative Site

Baja · Hungary

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
969

Novartis Investigative Site

Budapest · Hungary

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
970

Novartis Investigative Site

Szeged · Hungary

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
971

Novartis Investigative Site

Reykjavik · Iceland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
972

Novartis Investigative Site

Guntur · Andhra Pradesh · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
973

Novartis Investigative Site

Ahmedabad · Gujarat · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
974

Novartis Investigative Site

Vadodara · Gujarat · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
975

Novartis Investigative Site

Belagavi · Karnataka · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
976

Novartis Investigative Site

Mangalore · Karnataka · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
977

Novartis Investigative Site

Manipal · Karnataka · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
978

Novartis Investigative Site

Kochi · Kerala · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
979

Novartis Investigative Site

Nagpur · Maharashtra · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
980

Novartis Investigative Site

Nashik · Maharashtra · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
981

Novartis Investigative Site

Pune · Maharashtra · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
982

Novartis Investigative Site

New Delhi · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
983

Novartis Investigative Site

Bikaner · Rajasthan · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
984

Novartis Investigative Site

Chennai · Tamil Nadu · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
985

Novartis Investigative Site

Coimbatore · Tamil Nadu · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
986

Novartis Investigative Site

Hyderabad · Telangana · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
987

Novartis Investigative Site

Secunderabad · Telangana · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
988

Novartis Investigative Site

Ghaziabad · Uttar Pradesh · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
989

Novartis Investigative Site

Lucknow · Uttar Pradesh · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
990

Novartis Investigative Site

Dehradun · Uttarakhand · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
991

Novartis Investigative Site

Mysore · India

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
992

Novartis Investigative Site

Beersheba · Israel

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
993

Novartis Investigative Site

Haifa · Israel

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
994

Novartis Investigative Site

Holon · Israel

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
995

Novartis Investigative Site

Jerusalem · Israel

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
996

Novartis Investigative Site

Petah Tikva · Israel

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
997

Novartis Investigative Site

Ramat Gan · Israel

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
998

Novartis Investigative Site

Ancona · AN · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
999

Novartis Investigative Site

Bergamo · BG · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1000

Novartis Investigative Site

Bologna · BO · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1001

Novartis Investigative Site

Brescia · BS · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1002

Novartis Investigative Site

Cona · FE · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1003

Novartis Investigative Site

Florence · FI · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1004

Novartis Investigative Site

Pozzilli · IS · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1005

Novartis Investigative Site

Milan · MI · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1006

Novartis Investigative Site

Rozzano · MI · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1007

Novartis Investigative Site

Palermo · PA · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1008

Novartis Investigative Site

Perugia · PG · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1009

Novartis Investigative Site

Pisa · PI · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1010

Novartis Investigative Site

Roma · RM · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1011

Novartis Investigative Site

Salerno · SA · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1012

Novartis Investigative Site

Varese · VA · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1013

Novartis Investigative Site

Naples · Italy

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1014

Novartis Investigative Site

Nagoya · Aichi-ken · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1015

Novartis Investigative Site

Seto · Aichi-ken · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1016

Novartis Investigative Site

Hirosaki · Aomori · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1017

Novartis Investigative Site

Asahi · Chiba · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1018

Novartis Investigative Site

Funabashi · Chiba · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1019

Novartis Investigative Site

Matsudo · Chiba · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1020

Novartis Investigative Site

Kitakyushu · Fukuoka · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1021

Novartis Investigative Site

Ōgaki · Gifu · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1022

Novartis Investigative Site

Kure · Hiroshima · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1023

Novartis Investigative Site

Tsuchiura · Ibaraki · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1024

Novartis Investigative Site

Komatsu · Ishikawa-ken · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1025

Novartis Investigative Site

Takamatsu · Kagawa-ken · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1026

Novartis Investigative Site

Kawasaki · Kanagawa · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1027

Novartis Investigative Site

Sagamihara · Kanagawa · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1028

Novartis Investigative Site

Yokohama · Kanagawa · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1029

Novartis Investigative Site

Sendai · Miyagi · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1030

Novartis Investigative Site

Miyhazaki · Miyazaki · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1031

Novartis Investigative Site

Osaka · Osaka · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1032

Novartis Investigative Site

Sayama · Saitama · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1033

Novartis Investigative Site

Ōmihachiman · Shiga · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1034

Novartis Investigative Site

Bunkyo Ku · Tokyo · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1035

Novartis Investigative Site

Chuo Ku · Tokyo · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1036

Novartis Investigative Site

Chuo-ku · Tokyo · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1037

Novartis Investigative Site

Hachiōji · Tokyo · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1038

Novartis Investigative Site

Itabashi-ku · Tokyo · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1039

Novartis Investigative Site

Ōta-ku · Tokyo · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1040

Novartis Investigative Site

Ishikawa · Japan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1041

Novartis Investigative Site

Aguascalientes · Aguascalientes · Mexico

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1042

Novartis Investigative Site

Cuernavaca · Morelos · Mexico

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1043

Novartis Investigative Site

San Luis Potosí City · San Luis Potosí · Mexico

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1044

Novartis Investigative Site

Culiacan Sinaloa · Mexico

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1045

Novartis Investigative Site

Distrito Federal · Mexico

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1046

Novartis Investigative Site

Apeldoorn · Gelderland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1047

Novartis Investigative Site

Arnhem · Gelderland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1048

Novartis Investigative Site

Tiel · Gelderland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1049

Novartis Investigative Site

Heerlen · Limburg · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1050

Novartis Investigative Site

Tilburg · North Brabant · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1051

Novartis Investigative Site

Alkmaar · North Holland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1052

Novartis Investigative Site

Amsterdam · North Holland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1053

Novartis Investigative Site

Heemstede · North Holland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1054

Novartis Investigative Site

Deventer · Overijssel · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1055

Novartis Investigative Site

Zwolle · Overijssel · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1056

Novartis Investigative Site

Sneek · Provincie Friesland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1057

Novartis Investigative Site

Groningen · Provincie Groningen · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1058

Novartis Investigative Site

Leiden · South Holland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1059

Novartis Investigative Site

Leiderdorp · South Holland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1060

Novartis Investigative Site

The Hague · South Holland · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1061

Novartis Investigative Site

Amersfoort · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1062

Novartis Investigative Site

Gouda · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1063

Novartis Investigative Site

Hardenberg · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1064

Novartis Investigative Site

Nijmegen · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1065

Novartis Investigative Site

Utrecht · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1066

Novartis Investigative Site

Venlo · Netherlands

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1067

Novartis Investigative Site

Oslo · Norway

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1068

Novartis Investigative Site

Skedsmokorset · Norway

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1069

Novartis Investigative Site

Bielsko-Biala · Poland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1070

Novartis Investigative Site

Chrzanów · Poland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1071

Novartis Investigative Site

Gdansk · Poland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1072

Novartis Investigative Site

Gdynia · Poland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1073

Novartis Investigative Site

Lodz · Poland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1074

Novartis Investigative Site

Tarnów · Poland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1075

Novartis Investigative Site

Coimbra · Portugal

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1076

Novartis Investigative Site

Guimarães · Portugal

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1077

Novartis Investigative Site

Setúbal · Portugal

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1078

Research and Cardiovascular Corp

Ponce · Puerto Rico

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1079

Novartis Investigative Site

Buzău · Buzău · Romania

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1080

Novartis Investigative Site

Craiova · Dolj · Romania

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1081

Novartis Investigative Site

Baia Mare · Maramureş · Romania

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1082

Novartis Investigative Site

Bucharest · Romania

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1083

Novartis Investigative Site

Saint Petersburg · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1084

Novartis Investigative Site

Chelyabinsk · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1085

Novartis Investigative Site

Ivanovo · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1086

Novartis Investigative Site

Izhevsk · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1087

Novartis Investigative Site

Kemerovo · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1088

Novartis Investigative Site

Kirov · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1089

Novartis Investigative Site

Krasnodar · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1090

Novartis Investigative Site

Moscow · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1091

Novartis Investigative Site

Novosibirsk · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1092

Novartis Investigative Site

Perm · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1093

Novartis Investigative Site

Rostov-on-Don · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1094

Novartis Investigative Site

Ryazan · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1095

Novartis Investigative Site

Samara · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1096

Novartis Investigative Site

Saratov · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1097

Novartis Investigative Site

Sochy · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1098

Novartis Investigative Site

Tomsk · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1099

Novartis Investigative Site

Ulyanovsk · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1100

Novartis Investigative Site

Vsevolozhsk · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1101

Novartis Investigative Site

Yaroslavl · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1102

Novartis Investigative Site

Yekaterinburg · Russia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1103

Novartis Investigative Site

Trnava · Slovakia · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1104

Novartis Investigative Site

Bardejov · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1105

Novartis Investigative Site

Bratislava · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3WITHDRAWNNCT07517263 ↗
1106

Novartis Investigative Site

Handlová · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1107

Novartis Investigative Site

Komárno · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1108

Novartis Investigative Site

Košice · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1109

Novartis Investigative Site

Lučenec · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1110

Novartis Investigative Site

Nitra · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1111

Novartis Investigative Site

Nové Zámky · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1112

Novartis Investigative Site

Piešťany · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1113

Novartis Investigative Site

Považská Bystrica · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1114

Novartis Investigative Site

Prešov · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1115

Novartis Investigative Site

Rimavská Sobota · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1116

Novartis Investigative Site

Svidník · Slovakia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1117

Novartis Investigative Site

Ljubljana · Slovenia

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1118

Novartis Investigative Site

Johannesburg · Gauteng · South Africa

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1119

Novartis Investigative Site

Cape Town · South Africa

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1120

Novartis Investigative Site

George · Western Cape · South Africa

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1121

Novartis Investigative Site

Daegu · Dalseo gu · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1122

Novartis Investigative Site

Wŏnju · Gangwon-do · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1123

Novartis Investigative Site

Bundang Gu · Gyeonggi-do · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1124

Novartis Investigative Site

Suwon · Gyeonggi-do · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1125

Novartis Investigative Site

Incheon · Korea · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1126

Novartis Investigative Site

Seoul · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1127

Novartis Investigative Site

Busan · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1128

Novartis Investigative Site

Gwangju · South Korea

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1129

Novartis Investigative Site

Santiago Compostela · A Coruna · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1130

Novartis Investigative Site

Seville · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1131

Novartis Investigative Site

Badalona · Barcelona · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1132

Novartis Investigative Site

L'Hospitalet de Llobregat · Barcelona · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1133

Novartis Investigative Site

Santander · Cantabria · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1134

Novartis Investigative Site

Cáceres · Extremadura · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1135

Novartis Investigative Site

Reus · Tarragona · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1136

Novartis Investigative Site

A Coruña · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1137

Novartis Investigative Site

Barcelona · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1138

Novartis Investigative Site

Córdoba · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1139

Novartis Investigative Site

Huelva · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1140

Novartis Investigative Site

Madrid · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1141

Novartis Investigative Site

Málaga · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1142

Novartis Investigative Site

Zaragoza · Spain

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1143

Novartis Investigative Site

Gothenburg · Sweden

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1144

Novartis Investigative Site

Lund · Sweden

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1145

Novartis Investigative Site

Stockholm · Sweden

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1146

Novartis Investigative Site

Basel · Switzerland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1147

Novartis Investigative Site

Bern · Switzerland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1148

Novartis Investigative Site

Geneva · Switzerland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1149

Novartis Investigative Site

Lausanne · Switzerland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1150

Novartis Investigative Site

Liestal · Switzerland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1151

Novartis Investigative Site

Zurich · Switzerland

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1152

Novartis Investigative Site

Taichung · Taiwan ROC · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1153

Novartis Investigative Site

Hsinchu · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1154

Novartis Investigative Site

Kaohsiung City · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1155

Novartis Investigative Site

Keelung · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1156

Novartis Investigative Site

Tainan · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1157

Novartis Investigative Site

Taipei · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1158

Novartis Investigative Site

Taoyuan · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1159

Novartis Investigative Site

Yilan · Taiwan

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1160

Novartis Investigative Site

Izmir · Turkey (Türkiye)

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1161

Novartis Investigative Site

Ankara · Bilkent-Cankaya · Turkey (Türkiye)

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1162

Novartis Investigative Site

Istanbul · Kadikoy · Turkey (Türkiye)

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1163

Novartis Investigative Site

Eskişehir · Odunpazari · Turkey (Türkiye)

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1164

Novartis Investigative Site

Samsun · Samsun · Turkey (Türkiye)

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1165

Novartis Investigative Site

Mersin · Yenisehir · Turkey (Türkiye)

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1166

Novartis Investigative Site

Dorchester · Dorset · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1167

Novartis Investigative Site

London · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1168

Novartis Investigative Site

Preston · Lancashire · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1169

Novartis Investigative Site

Harrow · Middlesex · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1170

Novartis Investigative Site

Rochdale · North Manchester · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1171

Novartis Investigative Site

Portadown · Nothern Ireland · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1172

Novartis Investigative Site

Taunton · Somerset · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1173

Novartis Investigative Site

Chertsey · Surrey · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1174

Novartis Investigative Site

Newcastle upon Tyne · Tyne and Wear · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1175

Novartis Investigative Site

Sunderland · Tyne and Wear · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1176

Novartis Investigative Site

Cardiff · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1177

Novartis Investigative Site

Chichester · West Sussex · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1178

Novartis Investigative Site

Birmingham · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1179

Novartis Investigative Site

Bristol · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1180

Novartis Investigative Site

Bromwich · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1181

Novartis Investigative Site

Chesterfield · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1182

Novartis Investigative Site

Edinburgh · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1183

Novartis Investigative Site

Glasgow · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1184

Novartis Investigative Site

Leicester · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1185

Novartis Investigative Site

Liverpool · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1186

Novartis Investigative Site

Londonderry · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1187

Novartis Investigative Site

Manchester · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1188

Novartis Investigative Site

Middlesbrough · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1189

Novartis Investigative Site

Middlesex · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1190

Novartis Investigative Site

Newport · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1191

Novartis Investigative Site

Norwich · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1192

Novartis Investigative Site

Plymouth · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1193

Novartis Investigative Site

Rhyl · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1194

Novartis Investigative Site

Sheffield · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1195

Novartis Investigative Site

Swansea · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1196

Novartis Investigative Site

Tyne and Wear · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1197

Novartis Investigative Site

Wiltshire · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3RecruitingNCT07517263 ↗
1198

Novartis Investigative Site

Wrexham · United Kingdom

1 trial
Long-term safety extension study of pelacarsen for patients with elevated lipoprotein(a).
Novartis PharmaceuticalsPh 3ActiveNCT07517263 ↗
1199

Smiths Medical Center

Apache Junction · Arizona · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1200

Phoenix Medical Trials

Gilbert · Arizona · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1201

Onyx Clinical Research

Phoenix · Arizona · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1202

Southwest Kidney Institute - Surprise

Surprise · Arizona · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1203

John Muir Medical Center - Concord Campus

Concord · California · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1204

Ark Clinical Research - Fountain Valley

Fountain Valley · California · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1205

Thrive Clinical Research Group

Glendora · California · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1206

The Cardiovascular Center

Redding · California · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1207

FOMAT Medical Research - Santa Maria

Santa Maria · California · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1208

Integrated Clinical Research

Sherman Oaks · California · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1209

Lynn Institute of Denver

Aurora · Colorado · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1210

Legacy Clinical Trials

Colorado Springs · Colorado · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1211

OptumCare Clinical Trials, LLC

Golden · Colorado · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3CompletedNCT07157774 ↗
1212

FWD Clinical Research

Boca Raton · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3CompletedNCT07157774 ↗
1213

American Research Institute

Cutler Bay · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1214

K2 Medical Research - Daytona Beach

Daytona Beach · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1215

Arrow Clinical Trials

Daytona Beach · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1216

Soffer Health Institute

Hollywood · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1217

K2 MEDICAL Research THE VILLAGES

Lady Lake · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1218

Clinical Research of Central Florida

Lakeland · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1219

K2 Medical Research ORLANDO

Maitland · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1220

Dade Florida Clinical Research Center

Miami · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1221

Onhealth Research Center

Miami · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1222

Floridian Clinical Research, LLC

Miami Lakes · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1223

Precision Clinical Research

Sunrise · Florida · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1224

Masters of Clinical Research

Augusta · Georgia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1225

Elite Clinical Trials

Blackfoot · Idaho · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1226

Elite Clinical Trials

Rexburg · Idaho · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1227

Accellacare - DuPage

Lombard · Illinois · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1228

AMR Clinical

Niles · Illinois · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1229

IU Health Bloomington

Bloomington · Indiana · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1230

Franciscan Physician Network - Indiana Heart Physicians

Indianapolis · Indiana · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1231

Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital

Covington · Kentucky · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1232

Tulane University School of Medicine

New Orleans · Louisiana · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1233

MaineHealth Cardiology

Scarborough · Maine · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1234

Metropolitan Cardiovascular Consultants

Beltsville · Maryland · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1235

Lucida Clinical Trials

New Bedford · Massachusetts · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1236

Boeson Research MSO

Missoula · Montana · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1237

Desert Clinical Research, LLC

Henderson · Nevada · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1238

Clinical Research of South Nevada

Las Vegas · Nevada · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1239

Renascor Clinical Research

Reno · Nevada · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1240

Vector Clinical Trials

Sparks · Nevada · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1241

Clinical Research of Philadelphia

Pennington · New Jersey · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1242

Southwest Cardiovascular Center

Albuquerque · New Mexico · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1243

Capital Cardiology Associates

Albany · New York · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1244

Velocity Clinical Research, Syracuse

East Syracuse · New York · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1245

NYC Research

New York · New York · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1246

Weill Cornell Medical College

New York · New York · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1247

Rochester Clinical Research, LLC

Rochester · New York · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1248

SUNY Upstate Medical University

Syracuse · New York · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1249

Southgate Medical Group

West Seneca · New York · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1250

Velocity Clinical Research, Cincinnati, Mt. Auburn

Cincinnati · Ohio · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1251

Velocity Clinical Research, Cleveland

Cleveland · Ohio · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1252

Kaiser Permanente Sunnyside Medical Center

Clackamas · Oregon · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1253

Advanced Research Institute - Tigard

Portland · Oregon · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1254

Altoona Center For Clinical Research

Duncansville · Pennsylvania · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1255

M3 Wake Research - Charleston

Charleston · South Carolina · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1256

Circle Clinical Research

Sioux Falls · South Dakota · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1257

WR-Clinsearch, LLC

Chattanooga · Tennessee · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1258

Erlanger Health System

Chattanooga · Tennessee · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1259

The Jackson Clinic

Jackson · Tennessee · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1260

St. David's Heart & Vascular PLLC dba Austin Heart

Austin · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1261

Dallas VA Medical Center

Dallas · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1262

Southwest Family Medicine Associates

Dallas · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1263

Renal Disease Research Institute

Dallas · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1264

IntraCare

Dallas · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1265

Dallas Heart and Vascular Consultants, PA

Duncanville · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1266

Cedar Health Research - Fort Worth

Fort Worth · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1267

Orion Medical - Houston

Houston · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1268

GMG Clinical Research (DBA Radiance Clinical Research) - Lampasas

Lampasas · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1269

ERA Health Research-Texas

Midland · Texas · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1270

Ogden Clinic - Canyon View

Ogden · Utah · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1271

Advanced Research Institute

Ogden · Utah · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1272

Mary Washington Hospital

Fredericksburg · Virginia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1273

Carient Heart & Vascular - Manassas

Manassas · Virginia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1274

Manassas Clinical Research Center

Manassas · Virginia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1275

TPMG (Tidewater Physicians Multispecialty Group) Clinical Research

Newport News · Virginia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1276

York Clinical Research

Norfolk · Virginia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1277

Carient Heart and Vascular LLC-Reston

Reston · Virginia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1278

Dominion Medical Associates, Inc.

Richmond · Virginia · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1279

ERA Health Research - CardioNow - Lynnwood

Lynnwood · Washington · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1280

Universal Research Group

Tacoma · Washington · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1281

Central Washington Health Services Association d/b/a Confluence Health

Wenatchee · Washington · United States

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1282

CEC - Consultorios de Especialidades Cardiovasculares

Bahía Blanca · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1283

CONEXA Investigacion Clinica S.A.

Buenos Aires · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1284

Kynet

Buenos Aires · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1285

Cicemo Srl

Buenos Aires · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1286

Cardiología Palermo

Buenos Aires · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1287

Mautalen Salud e Investigación

Buenos Aires · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1288

CEMEDIAB

C.a.b.a. · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1289

Centro Medico Privado San Vicente Diabetes

Córdoba · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1290

CMD-Centro Médico y Diagnóstico por Imágenes

Junín · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1291

Polo de Salud Vistalba

Lujan de Cuyo · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1292

Fundacion Scherbovsky

Mendoza · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1293

Centro Rosarino de Investigaciones Clinicas (CRICs)

Rosario · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1294

Santa Maria de la Salud Centro Medico

San Isidro · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1295

Centro de Salud e Investigaciones Médicas

Santa Rosa · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1296

Centro de Investigaciones Medicas Temperley

Temperley · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1297

Instituto de Investigaciones Clinicas Zarate

Zárate · Argentina

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1298

Nightingale Research - Frankston

Frankston · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1299

Royal Hobart Hospital

Hobart · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1300

Ipswich Hospital

Ipswich · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1301

Sydney Cardiometabolic Centre

Liverpool · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1302

Maroochy Private Hospital

Maroochydore · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1303

Advara HeartCare - Milton

Milton · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1304

Southern Adelaide Diabetes & Endocrine Services

Oaklands Park · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1305

Regional Research Institute

Toowoomba · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1306

Latrobe Regional Health

Traralgon · Australia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1307

Medizinische Universität Graz

Graz · Austria

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1308

Cardio Metabolic Centre

Mattersburg · Austria

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1309

imed St. Pölten

Sankt Pölten · Austria

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1310

Imed19-privat

Vienna · Austria

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1311

AZORG Campus Aalst-Moorselbaan

Aalst · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1312

ANIMA Research

Alken · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1313

AZ Sint-Jan Brugge-Oostende AV

Bruges · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1314

Jan Yperman Ziekenhuis

Ieper · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1315

Kormont

Kluisbergen · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1316

Clinical Chc Montlégia

Liège · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1317

InoKura

Liège · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1318

Gezondheidshuis De Gloed

Machelen · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1319

Meclinas

Mechelen · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1320

Pneumocare

Namur · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1321

Artsen Netwerk De Schelde

Oudenaarde · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1322

Artsenpraktijk OHIO

Oudenaarde · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1323

Private Practice - Dr. De Watertoren

Tielt · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1324

Private Practice - Dr. Tim Decraecke (Zwalm)

Zwalm · Belgium

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1325

Hospital Sirio Libanes

Brasília · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1326

Hospital do Coração do Brasil

Brasília · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1327

Instituto de Ensino e Pesquisa Clinica do Ceara

Fortaleza · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1328

C-MEP - Centro Multidisciplinar de Ensino e Pesquisa

Joinville · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1329

CPHOSP Manaus Medicina, Ensino e Pesquisa

Manaus · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1330

Instituto Atena de Pesquisa Clinica

Natal · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1331

Hospital Maternidade E Pronto Socorro Santa Lucia

Poços de Caldas · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1332

Irmandade da Santa Casa de Misericórdia de Porto Alegre

Porto Alegre · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1333

Rede AME SAÚDE

Recife · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1334

Centro de Pesquisa Silvestre Santé

Rio Branco · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1335

Inovace Pesquisa Clínica

Salvador · Brazil

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1336

Riverside Cardiology and Diagnostic Imaging

Etobicoke · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1337

Winterberry Research Inc.

Hamilton · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1338

Institut de Cardiologie de Montreal

Montreal · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1339

IUCPQ

Québec · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1340

Bluewater Clinical Research Group Inc.

Sarnia · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1341

KMH Cardiology Centres - Stoney Creek

Stoney Creek · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1342

Unity Health Toronto, St. Michael's Hospital

Toronto · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1343

Fadia El Boreky Medicine

Waterloo · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1344

Clinical Research Solutions - Kitchener

Waterloo · Canada

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1345

Xuanwu Hospital Capital Medical University

Beijing · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1346

Beijing Pinggu District Hospital

Beijing · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1347

Xiangya Hospital Central South University

Changsha · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1348

The First People's Hospital of Changzhou

Changzhou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1349

Daqing People's Hospital

Daqing · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1350

The First People's Hospital of Foshan

Foshan · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1351

Zhujiang Hospital

Guangzhou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1352

Zhejiang Hospital

Hangzhou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1353

Jining No.1 People's Hospital

Jining · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1354

Huaihe Hospital of Henan University

Kaifeng · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1355

The First Affiliated Hospital of Henan University of Science &Technology

Luoyang Shi · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1356

Affiliated Hospital of Luzhou Medical College

Luzhou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1357

Nanchang People's Hospital

Nanchang · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1358

Jiangxi Provincial People's Hospital

Nanchang · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1359

Zhongda Hospital Southeast University

Nanjing · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1360

Jiangsu Province Hospital

Nanjing · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1361

The first affiliated hospital of Ningbo university

Ningbo · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1362

Shanghai Xuhui Central Hospital

Shanghai · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1363

The First Affiliated Hospital of Shantou University Medical College

Shantou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1364

The Second Affiliated Hospital of Soochow University

Suzhou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1365

The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

Wenzhou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1366

Xuzhou Central Hospital

Xuzhou · China

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1367

Kardiologie Stříbrný

Brno · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1368

MUDr. Karel Kamenik - Kardiologicka Ambulance

Brno · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1369

Kardio Chlumec

Chlumec nad Cidlinou · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1370

INTENDIA klinika s.r.o.

Chrudim III · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1371

DR. HAUS - Kardiologicka Ambulance

Český Krumlov · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1372

DIKa Centrum

Havířov · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1373

CTC Hodonin s.r.o.

Hodonín · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1374

Fakultni nemocnice Hradec Kralove

Hradec Králové · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1375

Cévní ambulance Nový Jičín

Nový Jičín · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1376

MUDr. Buchta s.r.o., Kardiologicka ambulance

Ostrava · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1377

Pratia Pardubice a.s.

Pardubice · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1378

Diabet2 s.r.o., diabetologicka a interni ambulance

Prague · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1379

Clinoxus

Prague · Czechia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1380

Centre Hospitalier d'Annecy

Epagny Metz-Tessy · France

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1381

Chu Grenoble Alpes

La Tronche · France

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1382

Centre Hospitalier Universitaire de Poitiers

Poitiers · France

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1383

Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord

Saint-Priest-en-Jarez · France

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1384

Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau

Tours · France

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1385

Klinische Forschung Berlin-Mitte

Berlin · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1386

FutureMeds GmbH

Berlin · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1387

Klinische Forschung Dresden

Dresden · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1388

Zentrum für klinische Prüfungen in der Facharztzentrum Dresden-Neustadt Betriebsgesellschaft mbH

Dresden · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1389

Unterfrintroper Hausarztzentrum Klinische Forschung

Essen · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1390

ClinPhenomics CVC GmbH

Frankfurt · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1391

Universitaetsklinikum Freiburg

Freiburg im Breisgau · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1392

Universitätsmedizin Greifswald

Greifswald · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1393

HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbH / -T

Hamburg · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1394

Velocity Clinical Research, Hamburg

Hamburg · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1395

Klinische Forschung Hamburg

Hamburg · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1396

Klinische Forschung Hannover-Mitte

Hanover · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1397

Klinische Forschung Karlsruhe

Karlsruhe · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1398

UKSH Campus Lübeck, Med. 1 - AG Meyhöfer

Lübeck · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1399

Dedicated Research Site FutureMeds

Offenbach · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1400

RED-Institut GmbH

Oldenburg · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1401

Klinische forschung Schwerin GmbH

Schwerin · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1402

Evangelisches Krankenhaus Witten

Witten · Germany

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1403

Evangelismos General Hospital of Athens

Athens · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1404

Athens Medical Center - Psychikon branch

Athens · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1405

General Hospital of Nikaia-Piraeus "Agios Panteleimon"

Nikaia Piraeus · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1406

University Hospital of Patras

Pátrai · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1407

G. Gennimatas General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1408

Euromedica General Clinic of Thessaloniki

Thessaloniki · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1409

Ippokrateio General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1410

European Interbalkan Medical Center

Thessaloniki · Greece

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1411

Semmelweis Egyetem

Budapest · Hungary

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1412

Gottsegen György Országos Kardiovaszkuláris Intézet

Budapest · Hungary

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1413

Cardiogeneral Egészségügyi Kft.

Budapest · Hungary

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1414

Arina Trial Research

Orosháza · Hungary

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1415

CoroMed

Pécs · Hungary

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1416

KomplexLabor Diagnosztika

Szeged · Hungary

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1417

Belagavi Institute of Medical Sciences - Belagavi

Belgavi · India

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1418

Eternal Heart Care Center and Research Institute

Jaipur · India

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1419

Kingsway Hospitals (Best Multispeciality Hospital in Nagpur)

Nagpur · India

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1420

Sir Ganga Ram Hospital

New Delhi · India

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1421

Ashirwad Hospital and Research Centre

Ulhasnagar · India

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1422

Azienda Ospedaliera di Caserta Sant' Anna e San Sebastiano

Caserta · Italy

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1423

Azienda Ospedaliero Universitaria S.Anna

Ferrara (Cona) · Italy

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1424

A.O.U. Policlinico Paolo Giaccone

Palermo · Italy

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1425

Fondazione IRCCS Policlinico San Matteo

Pavia · Italy

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1426

Azienda Ospedaliera Sant'Andrea

Rome · Italy

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1427

Akita University Hospital

Akita · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1428

Yamasaki Family Clinic

Amagasaki · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1429

Institute of Science Tokyo Hospital

Bunkyō · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1430

Shonan Fujisawa Tokushukai Hospital

Fujisawa · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1431

Tenjin Sogo Clinic

Fukuoka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1432

Hamanomachi Hospital

Fukuoka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1433

Fukuoka University Hospital

Fukuoka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1434

Kyushu Central Hospital

Fukuoka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1435

Gifu University Hospital

Gifu · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1436

Hachioji Diabetes Clinic

Hachioji-shi · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1437

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Hiroshima · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1438

Hiroshima Prefectural Hospital

Hiroshima · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1439

National Kohnodai Medical Center

Ichikawa · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1440

Nippon Medical School Chiba Hokusoh Hospital

Inzai · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1441

Nihon University Itabashi Hospital

Itabashiku · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1442

Shimane University Hospital

Izumo · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1443

Shonan Kamakura General Hospital

Kamakura · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1444

Mizonokuchi Okamoto Clinic

Kawasaki · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1445

Teikyo University Mizonokuchi Hospital

Kawasaki · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1446

Kobe University Hospital

Kobe · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1447

Yoshimura Clinic

Kumamoto · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1448

Omi Medical Center

Kusatsu · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1449

Toho University Ohashi Medical Center

Meguro-ku · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1450

Yokoi Clinic

Minoh · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1451

Nakamoto Internal Medicine Clinic

Mito · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1452

MinamiAkatsukaClinic

Mito · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1453

Nagasaki Harbor Medical Center

Nagasaki · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1454

Japan Public Health Association

Nagoya · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1455

Nakakinen clinic

Naka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1456

Nishiyamadou Keiwa Hospital

Naka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1457

International University of Health and Welfare Narita Hospital

Narita · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1458

Shimamura Memorial Hospital

Nerima-ku · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1459

Okayama Rosai Hospital

Okayama · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1460

Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai

Osaka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1461

Osaka Metropolitan University Hospital

Osaka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1462

Minamiosaka Hospital

Osaka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1463

Abe Clinic

Ōita · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1464

Sato Hospital - Osaki

Ōsaki · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1465

Toho University Omori Medical Center

Ōta-ku · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1466

Medical Corporation Koshinkai - Thyroid and Diabetes Clinic Nakanoshima

Sapporo · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1467

Cardiovascular Hospital Of Central Japan - Kitakanto Cardiovascular Hospital

Shibukawa · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1468

Clinical Research Hospital Tokyo

Shinjuku-ku · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1469

Tokyo Asbo Clinic

Tokyo · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1470

Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic

Yamato-shi · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1471

SHOWA Medical University Fujigaoka Hospital

Yokohama · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1472

Yokohama Minami Kyosai Hospital

Yokohama · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1473

Yokosuka City General Medical Center

Yokosuka · Japan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1474

Centro de Atencion al Diabetico Actopan

Actopan · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1475

Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.

Ciudad Madero · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1476

Centro de Investigación Clínica y Medicina Traslacional (CIMeT)

Guadalajara · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1477

Diseno y Planeacion en Investigacion Medica - Guadalajara - Calle Amado Nervo

Guadalajara · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1478

Instituto Jalisciense de Metabolismo

Guadalajara · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1479

Private Practice - Dr. Arechavaleta Granell Maria del Rosario

Guadalajara · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1480

Salud Cardiovascular

Guadalajara · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1481

Hermosillo Heart Team - Sinacor Hermosillo

Hermosillo · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1482

Accelerium Clinical Research

Mazatlán · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1483

Centro Médico Lic. Arturo Montiel Rojas ISSEMYM

Metepec · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1484

Centro de Investigacion en Artritis y Osteoporosis SC

Mexicali · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1485

RM Pharma Specialists - Unidad Especializada en Datos

Mexico City · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1486

Centro de Investigación Clinica Chapultepec

Mexico City · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1487

Private Practice - Dr. Eduardo Julián José Roberto Chuquiure Valenzuela

Mexico City · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1488

Instituto Nacional de Cardiologia Ignacio Chavez

Mexico City · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1489

Centro de Desarrollo Biomedico

Mérida · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1490

Kohler & Milstein Research S.A. De C.V.

Mérida · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1491

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares

México · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1492

CEINV Salud

Monterrey · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1493

IMED Internal Medicine Clin Trials

Monterrey · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1494

Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC

Morelia · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1495

Fundación Santos y de la Garza Evía I.B.P

San Pedro Garza García · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1496

Scientia Investigación Clínica TJ

Tijuana · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1497

Arké SMO S.A de C.V

Veracruz · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1498

FAICIC S. de R.L. de C.V.

Veracruz · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1499

Integradora Multidisciplinaria Del Grijalva - Sinacor Villahermosa

Villahermosa · Mexico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1500

Noordwest Ziekenhuisgroep

Alkmaar · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1501

EB Medical Research

Almere Stad · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1502

OLVG Oost

Amsterdam · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1503

Ziekenhuis Rijnstate

Arnhem · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1504

PT&R / PreCare Trial & Recruitment

Born · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1505

Ziekenhuis Bethesda

Hoogeveen · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1506

Canisius-Wilhelmina Ziekenhuis

Nijmegen · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1507

Albert Schweitzer Ziekenhuis, locatie Zwijndrecht

Zwijndrecht · Netherlands

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1508

Pro&Diagnostic

Bielsko-Biala · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1509

Centrum Medyczne "Hipokrates" S.C. Elżbieta I Grzegorz Grześk

Bydgoszcz · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1510

Euromedica

Grudziądz · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1511

Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero

Katowice · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1512

Centrum Medyczne Komorniki

Komorniki · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1513

FutureMeds - Lodz

Lodz · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1514

Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie

Lublin · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1515

IRMED

Piotrkow Trybunalski · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1516

Futuremeds Targowek

Warsaw · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1517

Przychodnia FutureMeds Wrocław

Wroclaw · Poland

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1518

Puerto Rico Health and Wellness Institute

Dorado · Puerto Rico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1519

Isis Clinical Research Center

Guaynabo · Puerto Rico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1520

Investigadores del Este

Humacao · Puerto Rico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1521

Research and Cardiovascular Corp.

Ponce · Puerto Rico

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1522

Cardioplus Center SRL

Baia Mare · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1523

Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu

Baloteşti · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1524

Centrul Medical Unirea

Brasov · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1525

Delta Health Care

Bucharest · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1526

The National Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. Dr. N. Paulescu"

Bucharest · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1527

Spitalul Clinic Profesor Doctor Theodor Burghele

Bucharest · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1528

Diabet Med

Bucharest · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1529

Milena Sante

Galați · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1530

Medical Practice SRL

Oradea · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1531

Spital Clinic Judetean de Urgenta Tg.Mures

Tg.Mures · Romania

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1532

National University Heart Centre, Singapore

Singapore · Singapore

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1533

National Heart Centre Singapore

Singapore · Singapore

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1534

Tan Tock Seng Hospital

Singapore · Singapore

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1535

Changi General Hospital

Singapore · Singapore

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1536

PreMedix

Bratislava · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1537

Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA

Bratislava · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1538

Narodny ustav srdcovych a cievnych chorob

Bratislava · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1539

Nemocnica s poliklinikou Dunajska Streda, a.s.

Dunajská Streda · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1540

Nemocnica s poliklinikou Sv. Lukasa Galanta, a. s.

Galanta · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1541

Cardio D&R

Košice · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1542

MediVet s.r.o.

Malacky · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1543

Nemocnica Malacky

Malacky · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1544

Nemocnica s poliklinikou Stefana Kukuru Michalovce a.s.

Michalovce · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1545

BENIMED s.r.o. Kardiologicka ambulancia

Piešťany · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1546

Vseobecna nemocnica Rimavska Sobota

Rimavská Sobota · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1547

Nemocnica s poliklinikou Spišská Nová Ves

Spišská Nová Ves · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1548

Vranovska Nemocnica

Vranov nad Topľou · Slovakia

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1549

Chosun University Hospital

Gwangju · South Korea

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1550

Hospital San Rafael - La Coruña

A Coruña · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1551

Hospital Universitari Vall d'Hebron

Barcelona · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1552

EAP Osona Sud - Alt Congost S.L.P

Centelles · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1553

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1554

Complejo Asistencial Universitario de León - Hospital de León

León · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1555

Complejo Hospitalario Ruber Juan Bravo

Madrid · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1556

Hospital La Princesa

Madrid · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1557

Hospital Universitario Infanta Leonor

Madrid · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1558

Hospital Quirón Málaga

Málaga · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1559

H.R.U Málaga - Hospital General

Málaga · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1560

CHOP - Hospital Universitario Montecelo

Pontevedra · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1561

Centro de Salud San Juan de la Cruz

Pozuelo de Alarcón · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1562

Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)

Seville · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1563

Hospital Quiron Infanta Luisa

Seville · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1564

Hospital Universitario de Toledo

Toledo · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1565

Hospital Vithas Valencia 9 de octubre

Valencia · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1566

Hospital Universitario Rio Hortega

Valladolid · Spain

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1567

National Cheng-Kung Uni. Hosp.

Tainan · Taiwan

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1568

South Eastern Health and Social Care Trust

Belfast · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1569

Glan Clwyd Hospital

Bodelwyddan · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1570

Bradford on Avon Health Centre

Bradford on Avon · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1571

FutureMeds - Liverpool

Bromborough · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1572

FutureMeds Glasgow - CPS Research

Glasgow · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1573

Velocity Clinical Research, High Wycombe

High Wycombe · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1574

HMC Health Group - Meadows Centre for Health

Hounslow · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1575

Raigmore Hospital

Inverness · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1576

Panthera Biopartners - Keele

Keele · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1577

Oak Tree Surgery

Liskeard · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1578

FutureMeds - London

London · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1579

EMS Healthcare

Macclesfield · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3Opening soonNCT07157774 ↗
1580

The Adam Practice

Poole · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1581

Rame Group Practice

Torpoint · United Kingdom

1 trial
Efficacy study of muvalaplin in reducing cardiovascular events in patients with high lipoprotein(a).
Eli Lilly and CompanyPh 3RecruitingNCT07157774 ↗
1582

First Affiliated Hospital of Xian Jiaotong University

Xi'an · Shaanxi · China

1 trial
NGGT006 gene therapy delivers a functional cholesterol-receptor gene to treat patients with severe inherited high cholesterol.
First Affiliated Hospital Xi'an Jiaotong UniversityPh 1 (early)RecruitingNCT06125847 ↗
1583

Chu de Nice

Nice · France · France

1 trial
Study examines lipoprotein(a) blood levels in lymphedema patients to assess cardiovascular risk.
Centre Hospitalier Universitaire de NiceRecruitingNCT05962827 ↗
1584

Centre antoine lacassagne

Nice · France · France

1 trial
Study examines lipoprotein(a) blood levels in lymphedema patients to assess cardiovascular risk.
Centre Hospitalier Universitaire de NiceTERMINATEDNCT05962827 ↗
1585

Research Site

Glendale · California · United States

1 trial
AZD4954 safety and activity tested in healthy volunteers and patients with high cholesterol or elevated lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
1586

Research Site

Inverness · Florida · United States

1 trial
AZD4954 safety and activity tested in healthy volunteers and patients with high cholesterol or elevated lipoprotein(a).
AstraZenecaPh 1RecruitingNCT06980428 ↗
1587

Alliance for Multispecialty Research, LLC

Daphne · Alabama · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1588

SEC Clinical Research

Dothan · Alabama · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1589

Alliance for Multispecialty Research, LLC

Mobile · Alabama · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1590

Sun City Clinical Research

Glendale · Arizona · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1591

Elite Clinical Studies, LLC

Phoenix · Arizona · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1592

Helios Clinical Research - Phoenix

Phoenix · Arizona · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1593

Absolute Clinical Research

Phoenix · Arizona · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1594

Synexus Clinical Research US, Inc./Orange Grove Family Practice

Tucson · Arizona · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1595

Cardiology and Medicine Clinic

Little Rock · Arkansas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1596

Valley Clinical Trials, Inc.

Covina · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1597

HB Clinical Trials - Fountain Valley

Fountain Valley · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1598

First Valley Medical Group

Lancaster · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1599

MemorialCare Health System - Long Beach Medical Center

Long Beach · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1600

Ark Clinical Research

Long Beach · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1601

Keck School of Medicine of USC

Los Angeles · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1602

Cardiovascular Research Foundation of Southern California

Los Angeles · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1603

Valley Clinical Trials, LLC dba Flourish Research

Northridge · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1604

Desert Oasis Healthcare Medical Group

Palm Springs · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1605

Artemis Institute for Clinical Research

San Diego · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1606

Care Access - Santa Clarita

Santa Clarita · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1607

Stanford University Medical Center

Stanford · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1608

Olive View-UCLA Medical Center

Sylmar · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1609

Care Access - Thousand Oaks

Thousand Oaks · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1610

Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.

Toluca Lake · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1611

InvivoCure

Van Nuys · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1612

Synexus Clinical Research US, Inc.

Vista · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1613

Millennium Clinical Trials

Westlake Village · California · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1614

CMR of Greater New Haven, LLC

Hamden · Connecticut · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1615

Hartford Hospital (HH)

Hartford · Connecticut · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1616

MedStar Washington Hospital Center

Washington D.C. · District of Columbia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1617

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Clearwater · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1618

Clinical Research of West Florida, Inc. (Clearwater)

Clearwater · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1619

Elite Cardiac Research Center

Hialeah · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1620

Westside Center for Clinical Research

Jacksonville · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1621

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Largo · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1622

South Florida Clinical Research Institute

Margate · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1623

Flourish Research - Miami, LLC

Miami · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1624

CTR Oakwater, LLC

Orlando · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1625

Innovative Research Institute - Port Charlotte

Port Charlotte · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1626

Clearwater Cardiovascular & Interventional Consultants M.D., P.A.

Safety Harbor · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1627

Clinical Research of West Florida

Tampa · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1628

Cardiology Partners Clinical Research Institute - Wellington

Wellington · Florida · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1629

American Clinical Trials - Acworth

Acworth · Georgia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1630

Atlanta Diabetes Associates

Atlanta · Georgia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1631

Emory University School of Medicine

Atlanta · Georgia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1632

East Coast Institute for Research - Canton

Canton · Georgia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1633

American Clinical Trials - Douglasville

Douglasville · Georgia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1634

Georgia Clinical Research - Lawrenceville

Lawrenceville · Georgia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1635

The Jones Center Clinical Research

Macon · Georgia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1636

CARE Institute

Meridian · Idaho · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1637

Chicago Clinical Research Institute

Chicago · Illinois · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1638

Alliance for Multispecialty Research, LLC

Niles · Illinois · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1639

Accellacare - DuPage

Winfield · Illinois · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1640

American Health Network of Indiana, LLC - Avon

Avon · Indiana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1641

Care Access - South Indianapolis

Indianapolis · Indiana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1642

American Health Network of Indiana, LLC - Franklin

Whiteland · Indiana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1643

AMR Clinical

Wichita · Kansas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1644

Qualmedica Research

Bowling Green · Kentucky · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1645

Alliance for Multispecialty Research, LLC

Lexington · Kentucky · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1646

Grace Research - Bossier

Bossier City · Louisiana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1647

Care Access - Lake Charles

Lake Charles · Louisiana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1648

Alliance for Multispecialty Research, LLC

New Orleans · Louisiana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1649

Louisiana Heart Center - Slidell

Slidell · Louisiana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1650

Sinai Hospital Of Baltimore

Baltimore · Maryland · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1651

Care Access - Baltimore

Baltimore · Maryland · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1652

MedStar Good Samaritan Hospital

Baltimore · Maryland · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1653

Jadestone Clinical Research

Beltsville · Maryland · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1654

Kur Research - Columbia Medical

Columbia · Maryland · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1655

MedStar Health Research Institute (MedStar Physician Based Research Network)

Hyattsville · Maryland · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1656

NECCR PrimaCare Research

Fall River · Massachusetts · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1657

Alliance for Multispecialty Research, LLC.

Dearborn · Michigan · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1658

Michigan Heart & Vascular Institute

Ypsilanti · Michigan · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1659

Memorial Hospital at Gulfport

Diamondhead · Mississippi · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1660

Clinvest Headlands Llc

Springfield · Missouri · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1661

Mercury Street Medical Group, PLLC

Butte · Montana · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1662

Las Vegas Endocrinology

Henderson · Nevada · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1663

DaVita Clinical Research - Las Vegas

Las Vegas · Nevada · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1664

Palm Research Center Tenaya

Las Vegas · Nevada · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1665

Internal Medicine Associates

Bridgeton · New Jersey · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1666

Atlantic Health System Overlook Medical Center

Summit · New Jersey · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1667

IMA Clinical Research Warren

Warren Township · New Jersey · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1668

Albany Medical College, Division of Community Endocrinology

Albany · New York · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1669

St. Francis Hospital & Heart Center

New Hyde Park · New York · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1670

NYU Langone Health

New York · New York · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1671

University of Rochester Medical Center

Rochester · New York · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1672

Saratoga Clinical Research

Saratoga Springs · New York · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1673

Stony Brook University

Stony Brook · New York · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1674

Triad Clinical Trials

Greensboro · North Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1675

Physician's East Endocrinology

Greenville · North Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1676

IMA Clinical Research Mount Airy

Mount Airy · North Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1677

Accellacare - Wilmington

Wilmington · North Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1678

Wake Forest Baptist Health

Winston-Salem · North Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1679

Velocity Clinical Research, Cleveland

Beachwood · Ohio · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1680

Velocity Clinical Research, Mt. Auburn

Cincinnati · Ohio · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1681

Velocity Clinical Research, Springdale

Cincinnati · Ohio · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1682

Cleveland Clinic

Cleveland · Ohio · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1683

Good Samaritan Regional Medical Center

Corvallis · Oregon · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1684

Heritage Valley Multispecialty Group, Inc

Beaver · Pennsylvania · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1685

Lancaster General Hospital

Lancaster · Pennsylvania · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1686

AHN Allegheny General Hospital

Pittsburgh · Pennsylvania · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1687

Preferred Primary Care Physicians

Uniontown · Pennsylvania · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1688

Accellacare Trident Cardiology

Charleston · South Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1689

Tribe Clinical Research, LLC

Greenville · South Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1690

Care Access - Mauldin

Mauldin · South Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1691

Accellacare - Mt Pleasant

Mt. Pleasant · South Carolina · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1692

Monument Health Rapid City Hospital

Rapid City · South Dakota · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1693

Alliance for Multispecialty Research, LLC

Knoxville · Tennessee · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1694

Care Access - Memphis 2

Memphis · Tennessee · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1695

Amarillo Heart Clinical Research Institute Inc.

Amarillo · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1696

IMA Clinical Research Austin

Austin · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1697

Headlands Horizons LLC

Brownsville · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1698

South Texas Clinical Research

Corpus Christi · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1699

Private Practice - Dr. James E. Race

Dallas · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1700

Baylor Soltero CV Research Center

Dallas · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1701

Cedar Health Research

Dallas · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1702

Cardio Voyage

Denison · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1703

South Texas Research Institute

Edinburg · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1704

Juno Research

Houston · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1705

Biopharma Informatic, LLC

Houston · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1706

PlanIt Research, PLLC

Houston · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1707

Accurate Clinical Research - Humble

Humble · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1708

The Heart Institute of East Texas

Lufkin · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1709

Wellness Clinical Research

McKinney · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1710

North Texas Research Associates

McKinney · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1711

Southern Endocrinology Associates

Mesquite · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1712

Clinical Advancement Center

San Antonio · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1713

Clinical Trials of Texas, LLC

San Antonio · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1714

Endeavor Clinical Trials

San Antonio · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1715

Consano Clinical Research, LLC

Shavano Park · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1716

DaVita Clinical Research - North Houston

Shenandoah · Texas · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1717

Alpine Research Organization

Clinton · Utah · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1718

Alliance for Multispecialty Research, LLC

Norfolk · Virginia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1719

IMA Clinical Research West Virginia

Morgantown · West Virginia · United States

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1720

Clínica Privada del Prado SRL

Alberdi · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1721

Fundación favaloro para la Docencia e Investigación Médica

Buenos Aires · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1722

CEDIC

CABA · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1723

Sanatorio Privado Duarte Quirós

Córdoba · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1724

CIDIM-Centro Integral de Diagnostico por Imagenes Marchegiani

Córdoba · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1725

MICA - Medicina e Investigación Cardiometabólica

Del Viso · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1726

Hospital Italiano de La Plata

La Plata · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1727

Clínica Privada Independencia

Munro · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1728

Centro Privado de Medicina Respiratoria

Paraná · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1729

CER medical Institute

Quilmes · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1730

Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica

Rosario · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1731

Centro Cardiovascular Salta

Salta · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1732

Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L

San Miguel de Tucumán · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1733

Go Centro Medico San Nicolás

San Nicolás · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1734

Clínica de Nefrología, Urología y Enfermedades Cardiovasculares

Santa Fe · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1735

Sanatorio San Martin

Venado Tuerto · Argentina

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1736

Advara HeartCare Leabrook

Adelaide · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1737

Paratus Clinical Research Western Sydney

Blacktown · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1738

Emeritus Research

Botany · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1739

Paratus Clinical Research Canberra

Bruce · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1740

Emeritus Research

Camberwell · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1741

Austin Health - Repatriation Hospital

Heidelberg West · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1742

Paratus Clinical Research Brisbane

Herston · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1743

Paratus Clinical Research Central Coast

Kanwal · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1744

Liverpool Hospital

Liverpool · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1745

Logan Hospital

Meadowbrook · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1746

AusTrials - Sunshine

Melbourne · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1747

University of the Sunshine Coast (UniSC) Clinical Trials - Noosa

Noosaville · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1748

Royal Perth Hospital

Perth · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1749

Momentum St. Leonards

Sydney · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1750

Townsville University Hospital

Townsville · Australia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1751

Medizinische Universitaet Innsbruck

Innsbruck · Austria

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1752

Université Libre de Bruxelles - Hôpital Erasme

Brussels · Belgium

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1753

Grand Hôpital de Charleroi

Charleroi · Belgium

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1754

AZ Sint-Blasius

Dendermonde · Belgium

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1755

AZ Maria Middelares

Ghent · Belgium

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1756

UZ Gent

Ghent · Belgium

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1757

Jessa Ziekenhuis

Hasselt · Belgium

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1758

Instituto Aramari Apo

Asa Norte · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1759

Santa Casa de Misericordia de Belo Horizonte

Belo Horizonte · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1760

Freire Pesquisa Clínica

Belo Horizonte · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1761

L2IP - Instituto de Pesquisas Clínicas

Brasília · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1762

Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Brasília

Brasília · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1763

PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR

Curitiba · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1764

Nucleo De Pesquisa Clinica

Curitiba · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1765

Centro de Pesquisas Clínicas Dr. Marco Mota

Maceió · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1766

CHN - Complexo Hospitalar de Niterói

Niterói · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1767

Hospital São Lucas da PUCRS

Porto Alegre · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1768

CAPED Centro Avancado Pesquisa e Diagnostica

Ribeirão Preto · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1769

Instituto D'Or Pesquisa e Ensino

Rio de Janeiro · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1770

Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador

Salvador · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1771

Hospital Ana Nery (HAN) - Salvador

Salvador · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1772

Hospital Da Bahia

Salvador · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1773

Faculdade de Medicina do ABC

Santo André · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1774

Centro Multidisciplinar de Estudos Clinicos

São Bernardo do Campo · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1775

BP - A Beneficencia Portuguesa de São Paulo

São Paulo · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1776

Hospital Alemao Oswaldo Cruz

São Paulo · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1777

Hospital do Coracao

São Paulo · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1778

IBCC - Núcleo de Pesquisa e Ensino

São Paulo · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1779

Instituto de Molestias Cardiovasculares de Tatui

Tatuí · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1780

Eurolatino Pesquisas Medicas

Uberlândia · Brazil

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1781

Cardio Health Clinical Trial - Brampton

Brampton · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1782

Milestone Research Inc.

London · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1783

Cardio Health Clinical Trial - London

London · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1784

Fraser Clinical Trials Inc

New Westminster · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1785

The Medical Arts Health Research Group

North Vancouver · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1786

Oakville Cardiovascular Research LP

Oakville · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1787

Medical Arts Health Research Group

Penticton · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1788

Clinique des Maladies Lipidiques de Québec

Québec · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1789

ALPHA Recherche Clinique

Québec · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1790

Unité de Recherche Clinique du CISSS des Laurentides

Saint-Jérôme · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1791

Cardio Health Clinical Trial - St. Thomas

St. Thomas · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1792

SMH Cardiology Clinical Trials

Surrey · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1793

Care Access - Cape Breton

Sydney · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1794

Centre de Medecine Metabolique de Lanaudiere (CMML)

Terrebonne · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1795

Corcare

Toronto · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1796

Diabetes Heart Research Centre

Toronto · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1797

ARC Biosystems

Vancouver · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1798

Winnipeg Clinic

Winnipeg · Canada

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1799

Beijing Chaoyang Hospital, Capital Medical University

Beijing · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1800

Beijing Friendship Hospital Affiliate of Capital University

Beijing · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1801

Changzhou Second People's Hospital

Changzhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1802

Chifeng Hospital

Chifeng · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1803

Dalian Municipal Central Hospital Affiliated of Dalian Medical University

Dalian · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1804

Shunde Hospital of Southern Medical Univesity

Foshan · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1805

Guangzhou First People's Hospital

Guangzhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1806

The Fourth Affiliated Hospital of Harbin Medical University

Harbin · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1807

Inner Mongolia People's Hospital

Hohhot · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1808

Huizhou Municipal Central Hospital

Huizhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1809

Jingzhou Central Hospital

Jingzhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1810

The First Hospital of Lanzhou University

Lanzhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1811

The Second Affiliated Hospital of Nanchang University

Nanchang · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1812

The Third Hospital of Nanchang

Nanchang · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1813

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Nanjing · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1814

The Second Affiliated Hospital of Nanjing Medical University

Nanjing · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1815

Guangxi People's Hospital

Nanning · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1816

Nanyang Second General Hospital

Nanyang · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1817

The First Affiliated Hospital of Nanyang Medical College

Nanyang · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1818

Ningbo First Hospital

Ningbo · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1819

Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1820

Shanghai Putuo District Center Hospital

Shanghai · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1821

Shanghai East Hospital

Shanghai · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1822

Shanghai No. 6 People's Hospital - Jinshan Central Hospital

Shanghai · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1823

The People's Hospital of Liaoning Province

Shenyang · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1824

Shenzhen Sun Yat-sen Cardiovascular Hospital

Shenzhen · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1825

The First Affiliated Hospital of Soochow University

Suzhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1826

Tianjin Fourth Centre Hospital

Tianjin · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1827

TEDA International Cardiovascular Hospital

Tianjin · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1828

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1829

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1830

Wuhan University Medical College - Hubei Zhongshan Hospital

Wuhan · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1831

Wuhan Asia Heart Hospital

Wuhan · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1832

Wuxi People's Hospital

Wuxi · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1833

Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army

Xi'an · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1834

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1835

Xiamen Cardiovascular Hospital

Xiamen · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1836

General Hospital of Ningxia Medical University

Yinchuan · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1837

The First People's Hospital of Yueyang

Yueyang · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1838

The Second Affiliated Hospital of Zhengzhou University

Zhengzhou · China

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1839

MEDICUS SERVICES s.r.o., kardiologicka ambulance

Brandýs nad Labem · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1840

Vojenská Nemocnice Brno

Brno · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1841

Kardiologicka ambulance

Litovel · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1842

EDUMED - Náchod

Náchod · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1843

Agentura Science Pro

Olomouc · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1844

PreventaMed

Olomouc · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1845

Kardiologicka a Angiologicka Ambulance

Ostrava · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1846

Private Practice - Dr. Miroslav Koliba

Ostrava · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1847

Kardio Uhrineves

Prague · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1848

Synexus Czech

Prague · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1849

Nefrologie

Prague · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1850

Centrum Kardiovaskularni Mediciny

Prague · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1851

Nova kardiologie - Kardiologicka ambulance

Říčany · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1852

Kardiologicka ambulance MUDr. Ferkl s.r.o.

Trutnov · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1853

Clinical Trials Service s.r.o.

Uherské Hradiště · Czechia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1854

Sygehus Sønderjylland i Aabenraa

Aabenraa · Denmark

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1855

Aarhus Universitetshospital, Skejby

Aarhus · Denmark

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1856

Rigshospitalet

Copenhagen · Denmark

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1857

Esbjerg sygehus, Syddansk Universitetshospital

Esbjerg · Denmark

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1858

Herlev and Gentofte Hospital

Herlev · Denmark

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1859

Holbæk Sygehus

Holbæk · Denmark

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1860

Hôpital Avicenne

Bobigny · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1861

Hospices Civils de Lyon - Hopital Louis Pradel

Bron · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1862

CHRU Troussau

Chambray-lès-Tours · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1863

Centre Hospitalier Compiègne-Noyon

Compiègne · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1864

Centre Hospitalier Louis Pasteur

Le Coudray · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1865

Hôpital de la Conception

Marseille · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1866

Hôpital Saint Joseph

Marseille · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1867

CHU Montpellier Lapeyronie Hospital

Montpellier · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1868

Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau

Nîmes · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1869

Centre Hospitalier de Pau

Pau · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1870

CHU Bordeaux Haut-Leveque

Pessac · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1871

Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou

Rennes · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1872

CHU Charles Nicolle

Rouen · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1873

Polyclinique Vauban

Valenciennes · France

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1874

Klinikum am Plattenwald

Bad Friedrichshall · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1875

Praxis Rankestrasse

Berlin · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1876

DRK Kliniken Berlin - Köpenick

Berlin · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1877

Klinikum Bielefeld Mitte

Bielefeld · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1878

Universitaetsklinikum Koeln

Cologne · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1879

Medizentrum Essen Borbeck

Essen · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1880

BAG Diabeteszentrum Dr. Tews & Partner

Gelnhausen · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1881

Universitätsklinikum Jena

Jena · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1882

Universitätsmedizin Mannheim

Mannheim · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1883

Kardiologische Gemeinschaftspraxis am Park Sanssouci

Potsdam · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1884

Universitaet zu Koeln - Sana-Klinikum Remscheid GmbH - Klinik fuer Kardiologie, Pneumologie und Internisti -T

Remscheid · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1885

GPR Gesundheits- und Pflegezentrum Rüsselsheim

Rüsselsheim am Main · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1886

Zentrum für klinische Studien

Saint Ingbert · Germany

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1887

Athens Naval Hospital

Athens · Greece

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1888

General Hospital of Athens Laiko

Athens · Greece

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1889

Athens Medical Center

Athens · Greece

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1890

Attikon General University Hospital

Chaïdári · Greece

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1891

Iatriko Paleou Falirou Medical Center

Palaió Fáliro · Greece

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1892

Papageorgiou General Hospital of Thessaloniki

Thessaloniki · Greece

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1893

DRC Gyógyszervizsgáló Központ

Balatongyörök · Hungary

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1894

Privát Doktor Egészségügyi Zrt

Budapest · Hungary

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1895

Eszak-Pesti Centrumkorhaz-Honvedkorhaz

Budapest · Hungary

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1896

Debreceni Egyetem Klinikai Kozpont

Debrecen · Hungary

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1897

Sardar Patel Medical College

Bikaner · India

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1898

Shri Mahant Indiresh Hospital

Dehradun · India

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1899

Lisie Hospital

Kochi · India

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1900

Emek Medical Center

Afula · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1901

Soroka Medical Center

Beersheba · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1902

Rambam Health Care Campus

Haifa · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1903

Carmel Hospital

Haifa · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1904

Linn Medical Center

Haifa · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1905

Edith Wolfson Medical Center

Holon · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1906

Shaare Zedek Medical Center

Jerusalem · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1907

Hadassah Medical Center

Jerusalem · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1908

Meir Medical Center

Kfar Saba · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1909

Galilee Medical Center

Nahariya · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1910

Rabin Medical Center

Petah Tikva · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1911

Sheba Medical Center

Ramat Gan · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1912

Kaplan Medical Center

Rehovot · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1913

Clalit Health Services - Sakhnin Community Clinic

Sakhnin · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1914

Sourasky Medical Center

Tel Aviv · Israel

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1915

Ospedale Bassini

Cinisello Balsamo · Italy

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1916

AOU Policlinico Umberto I

Rome · Italy

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1917

Asahi Hospital - Asahi

Asahi · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1918

Asahikawa City Hospital

Asahikawa · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1919

Saiseikai Futsukaichi Hospital

Chikushino-shi · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1920

University of Yamanashi Hospital

Chūō · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1921

Tokyo-Eki Center-building Clinic

Chūōku · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1922

Fukuwa Clinic

Chūōku · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1923

Fukuoka Wajiro Hospital

Fukuoka · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1924

Public Matto Ishikawa Central Hospital

Hakusan · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1925

Hyogo Prefectural Harima-Himeji General Medical Center

Himeji · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1926

Tokai University Hospital

Isehara · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1927

Rinku General Medical Center

Izumisano · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1928

Takai Internal Medicine Clinic

Kamakura-shi · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1929

Ishikawa Prefectural Central Hospital

Kanazawa · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1930

National Hospital Organization Kanazawa Medical Center

Kanazawa · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1931

Kasugai Municipal Hospital

Kasugai · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1932

Kokura Memorial Hospital

Kitakyushu · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1933

Kobe City Medical Center General Hospital

Kobe · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1934

Komatsu Municipal Hospital

Komatsu · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1935

Jinnouchi Hospital

Kumamoto · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1936

Chugoku Rosai Hospital

Kure · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1937

Rakuwakai Marutamachi Hospital

Kyoto · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1938

Rakuwakai Otowa Hospital

Kyoto · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1939

Aizawa Hospital

Matsumoto · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1940

National Hospital Organization Tokyo Medical Center

Meguro-ku · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1941

Tokyo Saiseikai Central Hospital

Minatoku · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1942

Miyakonojo Medical Association Hospital - Tarobocho

Miyakonojō · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1943

Kanazawa Medical University Hospital

Mukai-awagasaki · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1944

Tachikawa Medical Center

Nagaoka · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1945

Shonan Oiso Hospital

Naka-gun · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1946

Nogata Clinic

Nakano · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1947

Okayama City General Medical Center Okayama City Hospital

Okayama · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1948

National Hospital Organization Okayama Medical Center

Okayama · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1949

Medical Corporation Sato Medical clinic

Ootaku · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1950

National Hospital Organization - Osaka National Hospital - Institute For Clinical Research

Osaka · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1951

Kansai Electric Power Hospital

Osaka · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1952

Osaki Citizen Hospital - Furukawahonami

Ōsaki · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1953

Saga University Hospital

Saga · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1954

Kitasato University Hospital

Sagamihara · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1955

Sanai Hospital - Saitama

Saitama · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1956

Heishinkai Medical Group ToCROM Clinic

Shinjuku-ku · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1957

National Center for Global Health and Medicine

Shinjyuku-ku · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1958

Medical Corporation Heishinkai OCROM Clinic

Suita-shi · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1959

Shizuoka Medical Center

Sunto-gun · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1960

Higashi Takarazuka Satoh Hospital

Takarazuka · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1961

Takasago Seibu Hospital

Takasago · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1962

National Hospital Organization Shinshu Ueda Medical Center

Ueda · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1963

Saiseikai Yokohamashi Tobu Hospital

Yokohama · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1964

Yokosukakyosai

Yokosuka · Japan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1965

Centro de Investigación Cardiometabólica de Aguascalientes

Aguascalientes · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1966

Hospital Cardiologica Aguescalientes

Aguascalientes · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1967

Enclifar Ensayos Clínicos Farmacológicos Sc

Chihuahua City · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1968

Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia

Durango · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1969

Diseno y Planeacion en Investigacion Medica

Guadalajara · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1970

Centro de Investigacion Medica Integral

Guadalajara · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1971

CINVEC Medica

Guadalajara · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1972

Investigación Médica Sonora, S.C.

Hermosillo · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1973

RM Pharma Specialists

Mexico City · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1974

Clínicos Asociados BOCM

Mexico City · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1975

Clinica Omega

Mexico City · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1976

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares

Mexico City · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1977

ProcliniQ Investigación Clínica SA de CV

Mexico City · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1978

Clinstile, S.A. de C.V.

México · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1979

Christus - Latam Hub Center of Excellence and Innovation S.C.

Monterrey · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1980

Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

Monterrey · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1981

Clinica de Enfermedades Crónicas y de Procedimientos Especiales

Morelia · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1982

Centro de Estudios Clínicos de Querétaro (CECLIQ)

Querétaro · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1983

PanAmerican Clinical Research - Querétaro - Avenida Antea

Querétaro · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1984

Centro de Investigacion Cardiovascular y Metabólica

Tijuana · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1985

Instituto Veracruzano en Investigación Clínica S.C.

Veracruz · Mexico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1986

Gelre Ziekenhuis

Apeldoorn · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1987

Rode Kruis Ziekenhuis

Beverwijk · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1988

Reinier de Graaf Ziekenhuis, locatie Delft

Delft · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1989

Deventer Ziekenhuis

Deventer · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1990

Slingeland Ziekenhuis

Doetinchem · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1991

Catharina Ziekenhuis

Eindhoven · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1992

Admiraal de Ruyter Ziekenhuis, locatie Goes

Goes · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1993

Groene Hart Ziekenhuis

Gouda · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1994

General Practitioners Research Institute (GPRI)

Groningen · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1995

Martini Ziekenhuis

Groningen · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1996

Spaarne Gasthuis, Haarlem Zuid

Haarlem · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1997

Saxenburgh Medisch Centrum

Hardenberg · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1998

Medische Centrum Leeuwarden

Leeuwarden · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
1999

Radboudumc

Nijmegen · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2000

Ikazia Ziekenhuis

Rotterdam · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2001

Antonius Ziekenhuis, locatie D&A Research and Genetics

Sneek · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2002

Haga Ziekenhuis locatie Leyweg

The Hague · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2003

ETZ TweeSteden

Tilburg · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2004

Maxima Medisch Centrum, locatie Veldhoven

Veldhoven · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2005

Zaans Medisch Centrum

Zaandam · Netherlands

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2006

Specderm Poznanska sp.j.

Bialystok · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2007

NZOZ Centrum Medyczne KERmed

Bydgoszcz · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2008

Centrum Medyczne INTERCOR Sp. z o.o.

Bydgoszcz · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2009

Polsko-Amerykańskie Kliniki Serca PAKS Małopolskie Centrum Sercowo-Naczyniowe

Chrzanów · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2010

Polsko-Amerykańskie Kliniki Serca

Dąbrowa Górnicza · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2011

Centrum Kliniczno-Badawcze

Elblag · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2012

Uniwersyteckie Centrum Kliniczne

Gdansk · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2013

Przychodnie Grudziądz

Grudziądz · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2014

Polsko-Amerykańskie Kliniki Serca

Kędzierzyn-Koźle · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2015

Pro Salus Centrum Medyczne

Lodz · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2016

1 Wojskowy Szpital Kliniczny w Lublinie

Lublin · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2017

CenterMed Lublin NZOZ

Lublin · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2018

Wielospecjalistyczny Szpital Samodzielny Publiczny Zakład Opieki Zdrowotnej w Nowej Soli

Nowa Sól · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2019

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu

Przemyśl · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2020

AKA-MED Centrum

Ruda Śląska · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2021

Polsko-Amerykańskie Kliniki Serca

Tychy · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2022

Clinical Best Solutions

Warsaw · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2023

Balsam Medica

Warsaw · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2024

Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś

Warsaw · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2025

NZOZ Centurm Medyczne SERAFIN-MED

Żarów · Poland

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2026

GCM Medical Group, PSC - Hato Rey Site

San Juan · Puerto Rico

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2027

CMI Cardiologie - Dr. Mercea Corina Delia

Baia Mare · Romania

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2028

C.M.D.T.A. Neomed

Brasov · Romania

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2029

Centrul Medical Endocrinologie si Diabet Dr. Paveliu

Bucharest · Romania

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2030

Centrul Medical Consultmed

Iași · Romania

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2031

Cardiomed Iași

Iași · Romania

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2032

Cardiomed

Târgu Mureş · Romania

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2033

Cliniq s.r.o.

Bratislava · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2034

ENDIAMED s.r.o

Dolný Kubín · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2035

JM-Interna s.r.o

Dolný Kubín · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2036

IN-DIA

Lučenec · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2037

NEDÚ - Národný endokrinologický a diabetologický ústav n.o.

Ľubochňa · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2038

Sin Azucar

Malacky · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2039

AMBORA s.r.o. Interna ambulancia

Martin · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2040

Fakultná nemocnica Nitra

Nitra · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2041

MEDIKALS

Piešťany · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2042

MEDISPOL

Prešov · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2043

ENRIN, s.r.o.

Rimavská Sobota · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2044

Tatratrial s.r.o.

Rožňava · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2045

Areteus s.r.o.

Trebišov · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2046

MediPrax, s.r.o.

Trstená · Slovakia

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2047

The Catholic University of Korea, Bucheon St. Mary's Hospital

Bucheon-si · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2048

Keimyung University Dongsan Hospital

Daegu · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2049

Eulji University Hospital

Daejeon · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2050

Boramae Medical Center

Dongjak-gu · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2051

Chonnam National University Hospital

Gwangju · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2052

Kyung Hee University Hospital

Seoul · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2053

Seoul National University Hospital

Seoul · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2054

Kyung Hee University Hospital at Gangdong

Seoul · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2055

Sejong General Hospital

Sosa-gu · South Korea

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2056

Hospital Universitario Fundacion ALcorcon

Alcorcón · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2057

Hospital Germans Trias i Pujol

Badalona · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2058

Hospital de la Santa Creu i Sant Pau

Barcelona · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2059

Hospital de Denia Marina Salud

Denia · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2060

Hospital Clínico Universitario Virgen de la Arrixaca

El Palmar, Murcia · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2061

Hospital de Cabueñes

Gijón · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2062

Hospital Universitari de Girona Doctor Josep Trueta

Girona · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2063

Hospital Lucus Augusti

Lugo · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2064

Hospital Universitario La Paz

Madrid · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2065

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2066

Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2067

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca

Salamanca · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2068

Hospital de Sant Joan Despí Moisès Broggi

Sant Joan Despí · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2069

Hospital Arnau de Vilanova

Valencia · Spain

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2070

Changhua Christian Hospital

Changhua County · Taiwan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2071

Fu Jen Catholic University Hospital

New Taipei City · Taiwan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2072

Chung Shan Medical University Hospital

Taichung · Taiwan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2073

National Cheng Kung University Hospital

Tainan · Taiwan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2074

National Yang Ming Chiao Tung University Hospital

Yilan · Taiwan

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2075

Hull Royal Infirmary

Hull · United Kingdom

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2076

Royal Free Hospital

London · United Kingdom

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2077

Royal Victoria Infirmary

Newcastle upon Tyne · United Kingdom

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2078

Salford Royal Hospital

Salford · United Kingdom

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2079

Torbay Hospital

Torquay · United Kingdom

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2080

Sunderland Royal Hospital

Tyne and Wear · United Kingdom

1 trial
Lepodisiran injection reduces cardiovascular events in patients with elevated lipoprotein(a) and heart disease.
Eli Lilly and CompanyPh 3NCT06292013 ↗
2081

Advanced Cardiovascular LLC

Alexander City · Alabama · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2082

University of Alabama Birmingham Saint Vincents Birmingham

Birmingham · Alabama · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2083

Alliance For Multispecialty Research - Daphne

Daphne · Alabama · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2084

Eastern Shore Research Institute

Fairhope · Alabama · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2085

CB Flock Research Corporation

Mobile · Alabama · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2086

Phoenix Clinical

Phoenix · Arizona · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2087

Elite Clinical Studies LLC

Phoenix · Arizona · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2088

Hero Clinical Research

Phoenix · Arizona · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2089

HonorHealth Research Institute

Scottsdale · Arizona · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2090

Lynn Institute of the Ozarks

Little Rock · Arkansas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2091

University of California San Diego

La Jolla · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2092

InvivoCure

Los Angeles · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2093

Clinical Trials Research - Sacramento

Roseville · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2094

Alliance Clinical Research

San Diego · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2095

Encompass Clinical Research

Spring Valley · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2096

Stanford Health Care

Stanford · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2097

Blue Coast Cardiology

Vista · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2098

Diablo Clinical Research

Walnut Creek · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2099

Focus Clinical Research

West Hills · California · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2100

UCHealth Memorial Central

Colorado Springs · Colorado · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2101

South Denver Cardiology Associates

Littleton · Colorado · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2102

Gandelman Cardiology, PC

Greenwich · Connecticut · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2103

ClinTrial Hamden

Hamden · Connecticut · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2104

Clearwater Cardiovascular Consultants

Clearwater · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2105

Proactive Clinical Research

Fort Lauderdale · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2106

Elite Cardiac Research Center LLC

Hialeah · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2107

East Coast Institute for Research, LLC

Lake City · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2108

Columbus Clinical Services LLC

Miami · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2109

Kendall South Medical Center

Miami · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2110

Inpatient Research Clinic, LLC

Miami Lakes · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2111

Panax Clinical Research

Miami Lakes · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2112

Indago Research and Health Center

Miami Lakes · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2113

Eminat, LLC

Miramar · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2114

Suncoast Clinical Research Inc

New Port Richey · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2115

Ocala Cardiovascular Research

Ocala · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2116

Ocala Research Institute, Inc

Ocala · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2117

Ormond Beach Clinical Research

Ormond Beach · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2118

Baptist Health Care

Pensacola · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2119

Denali Health Plant City

Plant City · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2120

FWD Clinical Research

Tamarac · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2121

Clinical Site Partners Orlando dba Flourish Research

Winter Park · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2122

Guardian Research Organization LLC

Winter Park · Florida · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2123

Emory University Hospital

Atlanta · Georgia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2124

East Coast Institute for Research

Canton · Georgia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2125

Northeast Georgia Medical Center Wisteria Building

Cumming · Georgia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2126

Georgia Clinical Research

Lawrenceville · Georgia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2127

St Lukes Idaho

Meridian · Idaho · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2128

Solaris Clinical Research

Meridian · Idaho · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2129

Endeavor Health-Northwest Community Healthcare

Arlington Heights · Illinois · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2130

Christie Clinic

Champaign · Illinois · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2131

Advocate Lutheran General Hospital

Park Ridge · Illinois · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2132

Alliance for Multispecialty Research LLC - Park Ridge

Park Ridge · Illinois · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2133

MediSphere Medical Research Center LLC

Evansville · Indiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2134

Parkview Research Center

Fort Wayne · Indiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2135

Franciscan Health Indianapolis

Indianapolis · Indiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2136

Ascension Saint Vincent Heart Center

Indianapolis · Indiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2137

Cardiovascular Research of Northwest Indiana LLC

Munster · Indiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2138

Reid Physician Associates

Richmond · Indiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2139

MercyOne Iowa Heart Center

West Des Moines · Iowa · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2140

Hutchinson Clinic PA

Hutchinson · Kansas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2141

University of Kansas Medical Center

Kansas City · Kansas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2142

Midwest Heart and Vascular Specialists

Overland Park · Kansas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2143

Graves Gilbert Clinic

Bowling Green · Kentucky · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2144

Baptist Health Lexington

Lexington · Kentucky · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2145

The Research Group of Lexington LLC

Lexington · Kentucky · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2146

Heart Clinic of Hammond

Covington · Louisiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2147

Louisiana Heart Center

Slidell · Louisiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2148

Monroe Research LLC

West Monroe · Louisiana · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2149

Johns Hopkins Hospital

Baltimore · Maryland · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2150

Metropolitan Cardiovascular Consultants LLC

Beltsville · Maryland · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2151

Suburban Hospital

Bethesda · Maryland · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2152

Flourish Research

Bowie · Maryland · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2153

Capitol Cardiology Associates

Lanham · Maryland · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2154

MedStar Health Research Institute

Olney · Maryland · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2155

Brigham and Womens Hospital

Boston · Massachusetts · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2156

Henry Ford Health System

Detroit · Michigan · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2157

Healthy Heart Cardiology

Grand Rapids · Michigan · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2158

MyMichigan Medical Center Midland - Clinical Research Department

Midland · Michigan · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2159

Advanced Cardiology Associates

Rochester Hills · Michigan · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2160

Revival Research Institute

Southfield · Michigan · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2161

Saint Marys Medical Center

Duluth · Minnesota · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2162

Health East Cancer Care

Maplewood · Minnesota · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2163

Mayo Clinic

Rochester · Minnesota · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2164

Methodist Hospital

Saint Louis Park · Minnesota · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2165

Jackson Heart Clinic

Jackson · Mississippi · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2166

Cardiology Associates Research LLC

Tupelo · Mississippi · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2167

Sisters of Saint Mary Health Heart and Vascular Care

Bridgeton · Missouri · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2168

Kansas City Veterans Affairs Medical Center

Kansas City · Missouri · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2169

Washington University

St Louis · Missouri · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2170

Bryan Heart

Lincoln · Nebraska · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2171

Physician Research Collaboration, LLC

Lincoln · Nebraska · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2172

Excel Clinical Research

Las Vegas · Nevada · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2173

American Institute of Medical Research

Las Vegas · Nevada · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2174

Las Vegas Clinical Trials

North Las Vegas · Nevada · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2175

Renown Institute for Heart and Vascular Health

Reno · Nevada · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2176

Advanced Heart Care LLC

Bridgewater · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2177

Advanced Heart and Vascular Institute of Hunterdon

Flemington · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2178

Clinical Reseach Philadelphia Pennington

Hamilton · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2179

Med Clinical Research Partners - Irvington

Irvington · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2180

New Jersey Medcare / New Jersey Heart

Linden · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2181

Saint Michaels Medical Center

Newark · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2182

Circuit Clinical / Optum Medical Care of New Jersey

Secaucus · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2183

The Heart House - Washington Township

Sewell · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2184

CardioMetabolic Collaborative Clinic

Somerset · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2185

Ima Clinical Research - Warren

Warren Township · New Jersey · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2186

Albany Medical College

Albany · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2187

Basil Clinical

Inwood · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2188

Rasai Research

Jackson Heights · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2189

Crystal Run Healthcare

Monroe · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2190

Mount Sinai Queens

New York · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2191

Niagara Falls Memorial Medical Center

Niagara Falls · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2192

Circuit Clinical Orchard Park Family Practice

Orchard Park · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2193

Hudson Valley Cardiovascular Physicians PC

Poughkeepsie · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2194

Saratoga Clinical Research, LLC

Saratoga Springs · New York · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2195

Duke University Health System

Durham · North Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2196

Moses H Cone Memorial Hospital

Greensboro · North Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2197

Triad Clinical Trials, LLC

Greensboro · North Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2198

ClinCept, LLC

Kinston · North Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2199

Piedmont Healthcare

Statesville · North Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2200

Accellacare Research of Wilmington

Wilmington · North Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2201

Wake Forest University Health Sciences

Winston-Salem · North Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2202

Lillestol Research LLC

Fargo · North Dakota · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2203

Aultman Cardiology Clinical Trials

Canton · Ohio · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2204

The Christ Hospital

Cincinnati · Ohio · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2205

Velocity Clinical Research - Cincinnati

Cincinnati · Ohio · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2206

Nexgen Research

Lima · Ohio · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2207

K and R Research

Marion · Ohio · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2208

Alliance for Multispecialty Research

Norman · Oklahoma · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2209

University of Pennsylvania

Philadelphia · Pennsylvania · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2210

Preferred Primary Care Physicians, Inc

Pittsburgh · Pennsylvania · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2211

Pottstown Medical Specialists Inc

Pottstown · Pennsylvania · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2212

Miriam Hospital

East Greenwich · Rhode Island · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2213

Pharmacorp Clinical Trials Inc

Charleston · South Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2214

Prisma Health Carolina Cardiology - Greenville

Gantt · South Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2215

Accellacare Charleston

Mt. Pleasant · South Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2216

Tribe Clinical Research - Spartanburg

Spartanburg · South Carolina · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2217

Erlanger Health, Inc.

Chattanooga · Tennessee · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2218

Apex Research Foundation, LLC

Jackson · Tennessee · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2219

Alliance for Multispecialty Research Knoxville

Knoxville · Tennessee · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2220

Ascension Saint Thomas

Nashville · Tennessee · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2221

Parkway Cardiology Associates

Oak Ridge · Tennessee · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2222

Tennessee Center for Clinical Trials

Tullahoma · Tennessee · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2223

PharmaTex Research, LLC

Amarillo · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2224

Texas Diabetes and Endocrinology

Austin · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2225

Ima Clinical Research

Austin · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2226

Pioneer Medical Associates

Carrollton · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2227

Baylor Scott and White Heart and Vascular Hospital-Dallas

Dallas · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2228

The Heartbeat Clinic

Dallas · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2229

Cedar Health Research, LLC

Dallas · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2230

Cedar Health Research, LLC

Euless · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2231

East Texas Cardiology PA

Houston · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2232

Cardiovascular Specialists of Willowbrook

Houston · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2233

Vital Heart and Vein

Humble · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2234

Tcr Institute Llc

Kingwood · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2235

Epic Clinical Research

Lewisville · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2236

Texas Tech University Health Sciences Center

Lubbock · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2237

North Dallas Research Associates

McKinney · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2238

Revival Research Institute

McKinney · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2239

Texas Institute of Cardiology

McKinney · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2240

Southern Endocrinology Associates PA

Mesquite · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2241

Orion Medical

Pasadena · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2242

Valley Institute of Research Plano

Plano · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2243

St Davids Heart & Vascular PLLC dba Austin Heart

San Marcos · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2244

Tyler Cardiovascular Consultants

Tyler · Texas · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2245

Alpine Research Organization

Layton · Utah · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2246

Inova Cardiology - Fairfax

Fairfax · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2247

Virginia Heart - Loudoun

Leesburg · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2248

Bon Secours Cardiology

Midlothian · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2249

Tidewater Physicians Multispecialty Group Clinical Research

Newport News · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2250

Alliance for Multispecialty Research Norfolk

Norfolk · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2251

Centricity Research

Suffolk · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2252

Selma Medical Associates

Winchester · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2253

Winchester Medical Center

Winchester · Virginia · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3TERMINATEDNCT07136012 ↗
2254

Western Washington Medical Group

Everett · Washington · United States

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2255

Canberra Hospital

Garran · Australian Capital Territory · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2256

Royal Prince Alfred Hospital

Camperdown · New South Wales · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2257

Novatrials

Charlestown · New South Wales · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2258

Concord Repatriation General Hospital

Concord · New South Wales · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2259

Orange Health Service

Orange · New South Wales · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2260

Wollongong Hospital

Wollongong · New South Wales · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2261

Advara HeartCare Wesley

Auchenflower · Queensland · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2262

Core Research Group Pty Ltd

Milton · Queensland · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2263

University of The Sunshine Coast Clinical Trials, Sippy Downs

Sippy Downs · Queensland · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2264

Dr Heart Pty Ltd

Woolloongabba · Queensland · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2265

Flinders Medical Centre

Bedford Park · South Australia · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2266

The Alfred Hospital

Melbourne · Victoria · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2267

Momentum Clinical Research - Sunshine

Melbourne · Victoria · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2268

Hollywood Private Hospital

Nedlands · Western Australia · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2269

Linear Clinical Research Limited

Nedlands · Western Australia · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2270

Clinitrials - West Perth

Perth · Western Australia · Australia

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2271

Centricity Research Calgary

Calgary · Alberta · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2272

Edmonton Cardiology Consultants

Edmonton · Alberta · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2273

Fraser Clinical Trials

New Westminster · British Columbia · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2274

SMH Cardiology Clinical Trials Incorporated

Surrey · British Columbia · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2275

ARC Biosystems Incorporated

Vancouver · British Columbia · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2276

Discovery Clinical Services Ltd

Victoria · British Columbia · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2277

Centricity Research Brampton

Brampton · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2278

Circulate Cardiac & Vascular Centre

Burlington · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2279

Cambridge Cardiac Care Centre

Cambridge · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2280

Hamilton Health Sciences Hamilton General Hospital

Hamilton · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2281

St Josephs Hospital

London · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2282

Elevate Clinical Research KMH Missisauga

Mississauga · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2283

Partners in Advanced Cardiac Evaluation

Newmarket · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2284

Oakville Cardiovascular Research

Oakville · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2285

Heart Health Institute Research Incorporated

Scarborough Village · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2286

Womens College Hospital

Toronto · Ontario · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2287

Montreal Heart Institute

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2288

Institut de recherches cliniques de Montreal

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2289

Centre de Recherche du Centre Hospitalier de l Universite de Montreal

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2290

Research Institute of McGill University Health Center - Glen Site

Montreal · Quebec · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗
2291

CIUSSS de l Estrie CHUS Hopital Fleurimont

Sherbrooke · Quebec · Canada

1 trial
Olpasiran prevents first major heart attacks or strokes in at-risk patients with elevated lipoprotein(a).
AmgenPh 3RecruitingNCT07136012 ↗